<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Ehlers-Danlos Syndrome - Disorder Mechanisms</title>
    <style>
        :root {
            --primary: #0f766e;
            --primary-light: #14b8a6;
            --primary-dark: #0d5c56;
            --secondary: #6366f1;
            --bg: #f0fdfa;
            --card-bg: #ffffff;
            --text: #134e4a;
            --text-muted: #5f7a78;
            --border: #ccfbf1;
            --accent-orange: #f59e0b;
            --accent-rose: #f43f5e;
            --accent-violet: #8b5cf6;
            --accent-sky: #0ea5e9;
            --banner-bg: #fef3c7;
            --banner-border: #f59e0b;
            --banner-text: #92400e;
        }

        * { box-sizing: border-box; margin: 0; padding: 0; }

        body {
            font-family: 'Segoe UI', system-ui, -apple-system, sans-serif;
            background: var(--bg);
            color: var(--text);
            line-height: 1.7;
        }

        .notice-banner {
            background: var(--banner-bg);
            color: var(--banner-text);
            border-bottom: 1px solid var(--banner-border);
            padding: 12px 16px;
            text-align: center;
            font-size: 0.95rem;
            cursor: pointer;
        }

        .container {
            max-width: 1100px;
            margin: 0 auto;
            padding: 24px;
        }

        /* Header */
        .page-header {
            background: linear-gradient(135deg, var(--primary) 0%, var(--primary-dark) 100%);
            color: white;
            padding: 40px 32px;
            border-radius: 16px;
            margin-bottom: 24px;
            position: relative;
            overflow: hidden;
        }

        .page-header::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -20%;
            width: 400px;
            height: 400px;
            background: rgba(255,255,255,0.05);
            border-radius: 50%;
        }

        .page-header h1 {
            font-size: 2.2rem;
            font-weight: 700;
            margin-bottom: 12px;
            position: relative;
        }

        .header-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 12px;
            align-items: center;
            position: relative;
        }

        .badge {
            display: inline-flex;
            align-items: center;
            padding: 6px 14px;
            border-radius: 20px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .badge-category {
            background: rgba(255,255,255,0.2);
            color: white;
        }

        .badge-mondo {
            background: var(--accent-sky);
            color: white;
        }

        .badge-mondo a {
            color: inherit;
            text-decoration: none;
        }

        .badge-mondo a:hover {
            text-decoration: underline;
        }

        /* Navigation */
        .breadcrumb {
            margin-bottom: 16px;
            font-size: 0.9rem;
        }

        .breadcrumb a {
            color: var(--primary);
            text-decoration: none;
        }

        .breadcrumb a:hover {
            text-decoration: underline;
        }

        .breadcrumb span {
            color: var(--text-muted);
        }

        /* Cards */
        .card {
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            padding: 24px;
            margin-bottom: 20px;
            box-shadow: 0 1px 3px rgba(0,0,0,0.04);
        }

        .card-header {
            display: flex;
            align-items: center;
            gap: 12px;
            margin-bottom: 16px;
            padding-bottom: 12px;
            border-bottom: 2px solid var(--border);
        }

        .card-icon {
            width: 36px;
            height: 36px;
            border-radius: 8px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 1.2rem;
        }

        .card-title {
            font-size: 1.1rem;
            font-weight: 600;
            color: var(--text);
        }

        .card-count {
            margin-left: auto;
            background: var(--bg);
            padding: 4px 12px;
            border-radius: 12px;
            font-size: 0.8rem;
            color: var(--text-muted);
        }

        /* Sections */
        .section-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(320px, 1fr));
            gap: 20px;
        }

        /* Tags */
        .tag-list {
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
        }

        .tag {
            padding: 6px 12px;
            border-radius: 6px;
            font-size: 0.85rem;
            font-weight: 500;
        }

        .tag-cell {
            background: #fce7f3;
            color: #9d174d;
        }

        .tag-gene {
            background: #dbeafe;
            color: #1e40af;
        }

        .tag-treatment {
            background: #ede9fe;
            color: #5b21b6;
        }

        .tag-env {
            background: #ccfbf1;
            color: #0f766e;
        }

        .tag-location {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-component {
            background: #f0fdf4;
            color: #166534;
        }

        .tag-complex {
            background: #faf5ff;
            color: #7e22ce;
        }

        .tag-bio {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-modifier {
            background: #fee2e2;
            color: #991b1b;
            text-transform: uppercase;
            letter-spacing: 0.02em;
        }

        .tag-parent {
            background: #e0e7ff;
            color: #3730a3;
        }

        .tag-classification {
            background: #fef3c7;
            color: #92400e;
        }

        .tag-mechanistic {
            background: #dbeafe;
            color: #1e40af;
        }

        .linkout {
            color: inherit;
            margin-left: 6px;
            font-size: 0.75rem;
            text-decoration: none;
            border-bottom: 1px dotted rgba(0, 0, 0, 0.2);
        }

        .classification-category {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.05em;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .mapping-section {
            margin-bottom: 16px;
        }

        .mapping-item {
            padding: 10px 12px;
            border: 1px solid #e2e8f0;
            border-radius: 8px;
            background: #ffffff;
            margin-bottom: 10px;
        }

        .mapping-title {
            font-size: 0.9rem;
            font-weight: 600;
            display: flex;
            flex-wrap: wrap;
            gap: 8px;
            align-items: baseline;
            margin-bottom: 6px;
        }

        .mapping-label {
            color: var(--text-muted);
            font-weight: 500;
        }

        .mapping-notes {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
        }

        .mapping-tree {
            margin-top: 6px;
            font-size: 0.75rem;
            color: var(--text-muted);
            list-style: none;
            padding-left: 0;
        }

        .mapping-tree li {
            margin: 2px 0;
        }

        /* Evidence styling */
        .evidence-toggle {
            cursor: pointer;
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 10px;
            user-select: none;
        }

        .evidence-toggle:hover {
            color: var(--primary);
        }

        .evidence-list {
            margin-top: 10px;
            padding-left: 0;
        }

        .evidence-item {
            padding: 12px 14px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .evidence-header {
            display: flex;
            align-items: center;
            flex-wrap: wrap;
            gap: 8px;
        }

        .evidence-ref {
            font-weight: 600;
            color: var(--secondary);
        }

        .evidence-ref a {
            color: inherit;
            text-decoration: none;
        }

        .evidence-ref a:hover {
            text-decoration: underline;
        }

        .evidence-support {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .support-SUPPORT { background: #dcfce7; color: #166534; }
        .support-PARTIAL { background: #fef3c7; color: #92400e; }
        .support-REFUTE { background: #fee2e2; color: #991b1b; }
        .support-NO_EVIDENCE { background: #f1f5f9; color: #64748b; }
        .support-WRONG_STATEMENT { background: #fecaca; color: #7f1d1d; }

        .evidence-source {
            font-size: 0.7rem;
            padding: 2px 8px;
            border-radius: 4px;
            font-weight: 600;
            text-transform: uppercase;
            background: #e2e8f0;
            color: #334155;
            transition: transform 120ms ease, box-shadow 120ms ease;
        }

        .evidence-support:hover,
        .evidence-source:hover {
            transform: translateY(-1px);
            box-shadow: 0 4px 10px rgba(0,0,0,0.08);
        }

        .source-HUMAN_CLINICAL { background: #e0f2fe; color: #075985; }
        .source-MODEL_ORGANISM { background: #fef9c3; color: #854d0e; }
        .source-IN_VITRO { background: #ede9fe; color: #5b21b6; }
        .source-COMPUTATIONAL { background: #cffafe; color: #0e7490; }
        .source-OTHER { background: #e5e7eb; color: #374151; }

        .evidence-snippet {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 8px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        .evidence-explanation {
            font-size: 0.85rem;
            color: var(--text);
            margin-top: 6px;
            line-height: 1.5;
        }

        .evidence-more {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-top: 6px;
            font-style: italic;
        }

        .findings-section {
            margin-top: 12px;
        }

        .findings-title {
            font-size: 0.75rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: var(--text-muted);
            margin-bottom: 6px;
        }

        .finding-item {
            padding: 10px 12px;
            background: #f8fafc;
            border-radius: 8px;
            margin-bottom: 8px;
            border: 1px solid #e2e8f0;
            font-size: 0.9rem;
        }

        .finding-statement {
            font-weight: 600;
            color: var(--text);
            margin-bottom: 6px;
            line-height: 1.5;
        }

        .finding-supporting {
            font-size: 0.85rem;
            color: var(--text-muted);
            margin-top: 6px;
            padding-left: 12px;
            border-left: 2px solid #cbd5e1;
            font-style: italic;
            line-height: 1.5;
        }

        /* Item containers with evidence */
        .item-box {
            padding: 16px;
            border-radius: 10px;
            margin-bottom: 12px;
        }

        .item-name {
            font-weight: 600;
            margin-bottom: 6px;
        }

        .item-desc {
            font-size: 0.9rem;
            line-height: 1.6;
            margin-bottom: 8px;
        }

        .item-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            margin-top: 8px;
        }

        /* Definitions */
        .definition-box {
            background: #ecfeff;
            border-left: 4px solid #0ea5e9;
        }
        .definition-box .item-name { color: #0c4a6e; }
        .definition-box .item-desc { color: #075985; }

        /* Inheritance */
        .inheritance-box {
            background: #fef9c3;
            border-left: 4px solid #ca8a04;
        }
        .inheritance-box .item-name { color: #92400e; }
        .inheritance-box .item-desc { color: #92400e; }

        .criteria-block {
            margin-top: 12px;
            padding: 12px;
            border-radius: 8px;
            border: 1px solid #bae6fd;
            background: rgba(255, 255, 255, 0.7);
        }

        .criteria-title {
            font-weight: 600;
            color: #0c4a6e;
            margin-bottom: 6px;
        }

        .criteria-meta {
            font-size: 0.8rem;
            color: var(--text-muted);
            margin-bottom: 8px;
        }

        .criteria-header {
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #0284c7;
            margin-top: 8px;
        }

        .criteria-list {
            margin-left: 18px;
            font-size: 0.9rem;
            line-height: 1.5;
            color: #0f172a;
        }

        .criteria-list li {
            margin-bottom: 6px;
        }

        .criteria-detail {
            display: block;
            font-size: 0.85rem;
            color: var(--text-muted);
        }

        /* Pathophysiology */
        .pathophys-box {
            background: linear-gradient(135deg, #fef3c7 0%, #fef9c3 100%);
            border-left: 4px solid var(--accent-orange);
        }
        .pathophys-box .item-name { color: #92400e; }
        .pathophys-box .item-desc { color: #78350f; }

        /* Histopathology */
        .histopathology-box {
            background: #fff7ed;
            border-left: 4px solid #fb923c;
        }
        .histopathology-box .item-name { color: #9a3412; }
        .histopathology-box .item-desc { color: #c2410c; }

        .histopathology-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #ffedd5;
            color: #c2410c;
        }

        /* Phenotypes */
        .phenotype-box {
            background: #f0fdf4;
            border-left: 4px solid #22c55e;
        }
        .phenotype-box .item-name { color: #166534; }
        .phenotype-box .item-desc { color: #15803d; }

        .phenotype-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #dcfce7;
            color: #15803d;
        }

        .phenotype-category {
            font-size: 0.75rem;
            color: #4ade80;
        }

        .phenotype-id a {
            font-size: 0.8rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .phenotype-id a:hover {
            text-decoration: underline;
        }

        /* Phenotype TOC strip */
        .pheno-toc {
            display: flex;
            flex-wrap: wrap;
            gap: 6px;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #e2e8f0;
            margin-bottom: 4px;
        }

        .pheno-toc-pill {
            display: inline-block;
            font-size: 0.78rem;
            padding: 3px 10px;
            border-radius: 12px;
            background: #dcfce7;
            color: #166534;
            text-decoration: none;
            cursor: pointer;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toc-pill:hover {
            background: #bbf7d0;
        }

        .pheno-toc-pill .pill-count {
            font-weight: 600;
            margin-left: 2px;
        }

        .pheno-toggle-all {
            font-size: 0.78rem;
            color: #16a34a;
            cursor: pointer;
            background: none;
            border: 1px solid #bbf7d0;
            border-radius: 6px;
            padding: 3px 10px;
            margin-left: auto;
            white-space: nowrap;
            transition: background 0.15s;
        }

        .pheno-toggle-all:hover {
            background: #f0fdf4;
        }

        /* Collapsible category groups */
        .phenotype-category-group {
            margin-bottom: 2px;
        }

        .phenotype-category-group summary {
            font-size: 0.85rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            color: #16a34a;
            margin: 0;
            padding: 10px 0 6px 0;
            border-bottom: 1px solid #bbf7d0;
            cursor: pointer;
            list-style: none;
            display: flex;
            align-items: center;
            gap: 6px;
        }

        .phenotype-category-group summary::-webkit-details-marker {
            display: none;
        }

        .phenotype-category-group summary .chevron {
            display: inline-block;
            width: 16px;
            height: 16px;
            transition: transform 0.15s;
            flex-shrink: 0;
        }

        .phenotype-category-group[open] summary .chevron {
            transform: rotate(90deg);
        }

        .phenotype-category-group summary .cat-count {
            font-size: 0.75rem;
            font-weight: 400;
            color: #15803d;
            background: #dcfce7;
            padding: 1px 7px;
            border-radius: 8px;
        }

        /* Phenotype Contexts */
        .phenotype-contexts {
            margin-top: 10px;
        }

        .phenotype-contexts-toggle {
            font-size: 0.8rem;
            color: var(--text-muted);
            cursor: pointer;
            user-select: none;
        }

        .phenotype-contexts-toggle:hover {
            color: var(--primary);
        }

        .context-card {
            padding: 10px 14px;
            margin-top: 8px;
            border-radius: 8px;
            background: #ecfdf5;
            border: 1px solid #a7f3d0;
            font-size: 0.88rem;
        }

        .context-header {
            display: flex;
            flex-wrap: wrap;
            align-items: center;
            gap: 6px;
            margin-bottom: 6px;
        }

        .context-label {
            font-size: 0.72rem;
            font-weight: 600;
            text-transform: uppercase;
            letter-spacing: 0.04em;
            padding: 2px 8px;
            border-radius: 4px;
        }

        .context-label-genetic {
            background: #dbeafe;
            color: #1e40af;
        }

        .context-label-sex {
            background: #fce7f3;
            color: #9d174d;
        }

        .context-label-population {
            background: #fef3c7;
            color: #92400e;
        }

        .context-label-age {
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-label-subtype {
            background: #ede9fe;
            color: #5b21b6;
        }

        .context-label-frequency {
            background: #dcfce7;
            color: #166534;
        }

        .context-gene-list {
            display: flex;
            flex-wrap: wrap;
            gap: 4px;
            margin: 4px 0;
        }

        .context-gene-tag {
            font-size: 0.78rem;
            font-weight: 600;
            padding: 1px 8px;
            border-radius: 4px;
            background: #bfdbfe;
            color: #1e3a8a;
        }

        .context-detail {
            font-size: 0.84rem;
            color: #065f46;
            line-height: 1.5;
        }

        .context-detail strong {
            color: #047857;
        }

        .context-freq {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #bbf7d0;
            color: #14532d;
            font-weight: 600;
        }

        .context-onset {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #e0e7ff;
            color: #3730a3;
        }

        .context-severity {
            font-size: 0.75rem;
            padding: 2px 8px;
            border-radius: 10px;
            background: #fef3c7;
            color: #92400e;
        }

        .context-notes {
            font-size: 0.84rem;
            color: #065f46;
            margin-top: 4px;
            line-height: 1.5;
        }

        /* Genetic */
        .genetic-box {
            background: #eff6ff;
            border-left: 4px solid #3b82f6;
        }
        .genetic-box .item-name { color: #1e40af; }
        .genetic-box .item-desc { color: #2563eb; }

        /* Treatment */
        .treatment-box {
            background: #faf5ff;
            border-left: 4px solid #8b5cf6;
        }
        .treatment-box .item-name { color: #5b21b6; }
        .treatment-box .item-desc { color: #7c3aed; }

        /* Environmental */
        .environmental-box {
            background: #f0fdfa;
            border-left: 4px solid #14b8a6;
        }
        .environmental-box .item-name { color: #0f766e; }
        .environmental-box .item-desc { color: #0d9488; }

        /* Biochemical */
        .biochemical-box {
            background: #fffbeb;
            border-left: 4px solid #f59e0b;
        }
        .biochemical-box .item-name { color: #92400e; }
        .biochemical-box .item-desc { color: #b45309; }

        /* Differential Diagnoses */
        .differential-box {
            background: #fef2f2;
            border-left: 4px solid #dc2626;
        }
        .differential-box .item-name { color: #7f1d1d; }
        .differential-box .item-desc { color: #b91c1c; }

        .differential-similarities {
            background: #fee2e2;
            border-left: 2px solid #dc2626;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-distinctions {
            background: #dcfce7;
            border-left: 2px solid #16a34a;
            padding: 10px 12px;
            border-radius: 6px;
            margin: 8px 0;
            font-size: 0.9rem;
        }

        .differential-similarities strong,
        .differential-distinctions strong {
            display: block;
            margin-bottom: 6px;
            font-size: 0.85rem;
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        .differential-similarities ul,
        .differential-distinctions ul {
            margin-left: 16px;
            line-height: 1.6;
        }

        .differential-similarities li,
        .differential-distinctions li {
            margin: 4px 0;
            font-size: 0.9rem;
        }

        /* Datasets */
        .dataset-box {
            background: #f0f9ff;
            border-left: 4px solid #0284c7;
        }
        .dataset-box .item-name { color: #0c4a6e; }
        .dataset-box .item-desc { color: #0369a1; }

        .tag-dataset {
            background: #e0f2fe;
            color: #0369a1;
        }

        .tag-organism {
            background: #fae8ff;
            color: #a21caf;
        }

        .tag-datatype {
            background: #dbeafe;
            color: #1d4ed8;
        }

        /* Clinical Trials */
        .clinical-trial-box {
            background: #f5f3ff;
            border-left: 4px solid #a855f7;
        }
        .clinical-trial-box .item-name { color: #6b21a8; }
        .clinical-trial-box .item-desc { color: #7e22ce; }

        .tag-phase {
            background: #ede9fe;
            color: #6b21a8;
        }

        .tag-status {
            background: #fce7f3;
            color: #9d174d;
        }

        .trial-nct a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .trial-nct a:hover {
            text-decoration: underline;
        }

        .dataset-accession a {
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            color: var(--secondary);
            text-decoration: none;
        }

        .dataset-accession a:hover {
            text-decoration: underline;
        }

        /* Subtypes */
        .subtype-box {
            background: #eef2ff;
            border-left: 4px solid var(--secondary);
        }
        .subtype-box .item-name { color: #3730a3; }
        .subtype-box .item-desc { color: #4f46e5; }
        .classification-header {
            font-size: 1rem;
            font-weight: 600;
            color: #4338ca;
            margin: 1.2rem 0 0.5rem 0;
            padding-bottom: 0.3rem;
            border-bottom: 2px solid #c7d2fe;
            text-transform: capitalize;
        }
        .subtype-meta {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin: 0.3rem 0;
        }
        .subtype-freq-badge {
            background: #dbeafe;
            color: #1e40af;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-gene-tag {
            background: #fef3c7;
            color: #92400e;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-inheritance-tag {
            background: #ede9fe;
            color: #5b21b6;
            padding: 0.15rem 0.5rem;
            border-radius: 9999px;
            font-size: 0.8rem;
            font-weight: 500;
        }
        .subtype-term-link {
            font-size: 0.8rem;
            color: #6366f1;
            text-decoration: none;
        }
        .subtype-term-link:hover { text-decoration: underline; }
        .subtype-children {
            margin: 0.4rem 0 0.2rem 1rem;
            padding: 0;
            list-style: none;
        }
        .subtype-children li {
            font-size: 0.85rem;
            color: #4338ca;
            padding: 0.1rem 0;
        }
        .subtype-children li::before {
            content: "‚Ü≥ ";
            color: #a5b4fc;
        }

        /* Stats bar */
        .stats-bar {
            display: flex;
            gap: 24px;
            padding: 20px 24px;
            background: var(--card-bg);
            border-radius: 12px;
            border: 1px solid var(--border);
            margin-bottom: 24px;
            flex-wrap: wrap;
        }

        .stat-item {
            text-align: center;
        }

        .stat-link {
            text-decoration: none;
            color: inherit;
        }

        .stat-value {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
        }

        .stat-label {
            font-size: 0.8rem;
            color: var(--text-muted);
            text-transform: uppercase;
            letter-spacing: 0.05em;
        }

        /* YAML preview */
        .yaml-preview {
            background: #1e293b;
            color: #e2e8f0;
            padding: 20px;
            border-radius: 8px;
            overflow-x: auto;
            font-family: 'Fira Code', 'Consolas', monospace;
            font-size: 0.85rem;
            line-height: 1.5;
            max-height: 400px;
            overflow-y: auto;
        }

        .yaml-content {
            display: none;
        }

        .yaml-content.show {
            display: block;
        }

        /* Footer */
        .page-footer {
            margin-top: 40px;
            padding-top: 20px;
            border-top: 1px solid var(--border);
            text-align: center;
            color: var(--text-muted);
            font-size: 0.85rem;
        }

        .page-footer a {
            color: var(--primary);
            text-decoration: none;
        }

        .page-footer a:hover {
            text-decoration: underline;
        }

        /* Responsive */
        @media (max-width: 768px) {
            .page-header h1 { font-size: 1.6rem; }
            .stats-bar { gap: 16px; }
            .section-grid { grid-template-columns: 1fr; }
        }
        /* Mermaid graph */
        .mermaid-container {
            text-align: center;
            margin: 20px 0;
            padding: 20px;
            background: white;
            border-radius: 8px;
            border: 1px solid var(--border);
            overflow-x: auto;
        }

        .mermaid svg {
            max-width: 100%;
            height: auto;
        }

        .graph-warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 12px 16px;
            margin-bottom: 16px;
            font-size: 0.85rem;
            color: #92400e;
        }

        .graph-warning strong {
            display: block;
            margin-bottom: 4px;
        }

        .graph-warning ul {
            margin: 8px 0 0 20px;
            padding: 0;
        }

        .graph-warning li {
            margin: 4px 0;
        }
    </style>
    <script src="https://cdn.jsdelivr.net/npm/mermaid@10/dist/mermaid.min.js"></script>
    <script>
        mermaid.initialize({
            startOnLoad: true,
            theme: 'default',
            flowchart: {
                htmlLabels: true,
                curve: 'basis'
            }
        });
    </script>
</head>
<body>
    <div class="notice-banner" role="button" tabindex="0">This resource is in its pre-alpha development stage. Content is actively being curated and may be incomplete or subject to change.</div>
    

    

    
    

    
    

    

    

    

    

    

    <div class="container">
        <nav class="breadcrumb">
            <a href="../../app/index.html">Browse All</a>
            <span> / </span>
            <span>Ehlers-Danlos Syndrome</span>
        </nav>

        <header class="page-header">
            <h1>Ehlers-Danlos Syndrome</h1>
            <div class="header-meta">
                
                <span class="badge badge-category">Genetic</span>
                
                
                <span class="badge badge-mondo">
                    <a href="http://purl.obolibrary.org/obo/MONDO_0020066" target="_blank">
                        MONDO:0020066
                    </a>
                </span>
                
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Connective Tissue Disorder</span>
                
                <span class="badge badge-category" style="background: rgba(255,255,255,0.1);">Inherited Disorder</span>
                
            </div>
            
        </header>

        <!-- Stats bar -->
        
        
        
        
        
        
        
        
        
        
        
        
        
        <div class="stats-bar">
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Mappings</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Definitions</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Inheritance</div>
            </div>
            
            
            <a class="stat-link" href="#pathophysiology">
            <div class="stat-item">
                <div class="stat-value">6</div>
                <div class="stat-label">Mechanisms</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Histopathology</div>
            </div>
            
            
            <a class="stat-link" href="#phenotypes">
            <div class="stat-item">
                <div class="stat-value">13</div>
                <div class="stat-label">Phenotypes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#genetic">
            <div class="stat-item">
                <div class="stat-value">9</div>
                <div class="stat-label">Genes</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#treatments">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Treatments</div>
            </div>
            </a>
            
            
            <a class="stat-link" href="#subtypes">
            <div class="stat-item">
                <div class="stat-value">4</div>
                <div class="stat-label">Subtypes</div>
            </div>
            </a>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Differentials</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Datasets</div>
            </div>
            
            
            <div class="stat-item">
                <div class="stat-value">0</div>
                <div class="stat-label">Trials</div>
            </div>
            
        </div>

        <!-- Classifications -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üè∑</div>
                <h2 class="card-title">Classifications</h2>
            </div>
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Harrison's Chapter</div>
                <div class="tag-list">
                    
                    <span class="tag tag-classification">musculoskeletal system disorder</span>
                    
                    <span class="tag tag-classification">connective tissue disease</span>
                    
                    <span class="tag tag-classification">hereditary disease</span>
                    
                </div>
            </div>
            
            
            <div style="margin-bottom: 16px;">
                <div class="classification-category">Mechanistic Nosology</div>
                <div class="tag-list">
                    
                    <span class="tag tag-mechanistic">collagenopathy</span>
                    
                </div>
            </div>
            
            
            
            
            
        </div>
        

        <!-- Mappings -->
        

        <!-- Definitions -->
        

        <!-- Inheritance -->
        

        <!-- Subtypes -->
        
        <div class="card" id="subtypes">
            <div class="card-header">
                <div class="card-icon" style="background: #eef2ff; color: #4f46e5;">‚óÜ</div>
                <h2 class="card-title">Subtypes</h2>
                <span class="card-count">4</span>
            </div>
            
            
            
                
                
                    
                
                
            
                
                
                
            
                
                
                
            
                
                
                
            
            
                
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Classical EDS (cEDS)
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Characterized by skin hyperextensibility, atrophic scarring, and joint hypermobility.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28192633" target="_blank">PMID:28192633</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Classical EDS is a heritable disorder of connective tissue. Patients are affected with joint hypermobility, skin hyperextensibilty, and skin fragility leading to atrophic scarring and significant bruising."</div>
                
                
                <div class="evidence-explanation">This reference directly supports the claim that Classical EDS (cEDS) is characterized by joint hypermobility, skin hyperextensibility, and atrophic scarring.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Hypermobile EDS (hEDS)
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Characterized by generalized joint hypermobility, often with recurrent joint dislocations and chronic pain.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20301456" target="_blank">PMID:20301456</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hypermobile Ehlers-Danlos syndrome (hEDS) is characterized by generalized joint hypermobility, joint instability, pain, soft and hyperextensible skin with atrophic scars and easy bruising..."</div>
                
                
                <div class="evidence-explanation">While hEDS is characterized by generalized joint hypermobility and chronic pain, the provided literature does not emphasize recurrent joint dislocations as a defining characteristic.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31582002" target="_blank">PMID:31582002</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Symptomatic joint hypermobility can result from soft tissue injury or muscular strain caused by muscular imbalance"</div>
                
                
                <div class="evidence-explanation">This article supports the characterization of hEDS with generalized joint hypermobility, recurrent joint dislocations, and chronic pain.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28145611" target="_blank">PMID:28145611</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"‚ÄúThe hypermobile type of Ehlers-Danlos syndrome (hEDS) is likely the most common hereditary disorder of connective tissue. It has been described largely in those with musculoskeletal complaints including joint hypermobility, joint subluxations/dislocations, as well as skin and soft tissue..."</div>
                
                
                <div class="evidence-explanation">This provides direct support for the statement, noting joint hypermobility, recurrent dislocations, and associated chronic pain in hEDS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Vascular EDS (vEDS)
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Most severe form, characterized by thin, translucent skin, arterial, intestinal, and uterine fragility.</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33650410" target="_blank">PMID:33650410</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The vascular subtype of EDS (type IV) is defined by characteristic facial features, translucent skin, easy bruising, and spontaneous arterial rupture and visceral perforation of such organs as the uterus and intestines, with possible life-threatening consequences."</div>
                
                
                <div class="evidence-explanation">This excerpt directly supports the statement by confirming that vEDS is characterized by thin, translucent skin, and fragility of arteries, intestines, and uterus.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32941194" target="_blank">PMID:32941194</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Vascular Ehlers-Danlos syndrome (vEDS) is the most severe form of EDS, affecting the synthesis of type III collagen. It is notable for decreased life expectancy and morbidity, including spontaneous vessel rupture."</div>
                
                
                <div class="evidence-explanation">This excerpt supports the statement by indicating that vEDS is the most severe form of EDS and is associated with significant arterial fragility.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29709596" target="_blank">PMID:29709596</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Life-threatening arterial aneurysms, dissections and ruptures of medium-sized and large arteries are a hallmark of the vascular subtype of EDS, caused by a molecular defect in collagen type III, an important constituent of blood vessel walls and hollow organs."</div>
                
                
                <div class="evidence-explanation">This excerpt supports the statement by mentioning the severe arterial fragility associated with vEDS.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                </div>
                
                <div class="item-box subtype-box">
                    <div class="item-name">
                        Kyphoscoliotic EDS (kEDS)
                        
                    </div>
                    <div class="subtype-meta">
                        
                        
                        
                    </div>
                    
                    <div class="item-desc">Characterized by kyphoscoliosis, hypotonia, and ocular fragility</div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/18155911" target="_blank">PMID:18155911</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) (OMIM 225400) is an inherited connective tissue disorder characterized by hypotonia and kyphoscoliosis at birth, joint hypermobility, and skin hyperelasticity and fragility."</div>
                
                
                <div class="evidence-explanation">The reference describes the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) as having kyphoscoliosis and hypotonia.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20301635" target="_blank">PMID:20301635</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"PLOD1-related kyphoscoliotic Ehlers-Danlos syndrome (PLOD1-kEDS) is characterized by hypotonia, generalized joint hypermobility, early-onset kyphoscoliosis, skin fragility, and ocular abnormality."</div>
                
                
                <div class="evidence-explanation">The reference explicitly lists kyphoscoliosis, hypotonia, and ocular abnormalities as characteristics of PLOD1-kEDS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                </div>
                
            
        </div>
        

        <!-- Comorbidities -->
        

        <!-- Pathophysiology -->
        
        <div class="card" id="pathophysiology">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">‚öô</div>
                <h2 class="card-title">Pathophysiology</h2>
                <span class="card-count">6</span>
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Collagen Abnormalities</div>
                
                <div class="item-desc">Mutations in genes encoding collagen or collagen-modifying enzymes lead to defective collagen synthesis and assembly.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        collagen fibril organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030199" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        collagen biosynthetic process
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0032964" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7086195" target="_blank">PMID:7086195</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Several abnormalities in collagen biosynthesis have been described in patients with Ehlers-Danlos syndrome. Examples of collagen structural mutations as well as post-translational enzymatic defects have been detected."</div>
                
                
                <div class="evidence-explanation">This reference confirms that mutations affecting collagen synthesis and enzymes responsible for collagen modification are associated with Ehlers-Danlos Syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37187299" target="_blank">PMID:37187299</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Vascular Ehlers-Danlos Syndrome (vEDS) is a rare autosomal dominant disease caused by mutations in the COL3A1 gene."</div>
                
                
                <div class="evidence-explanation">This reference identifies specific gene mutations (e.g., COL3A1) responsible for defective collagen synthesis leading to Ehlers-Danlos Syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/2010058" target="_blank">PMID:2010058</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Recently, several mutations in three other collagen genes (COL2A1, COL3A1, and COL4A5) have been found in probands with genetic diseases involving tissues rich in these collagens."</div>
                
                
                <div class="evidence-explanation">The reference supports the statement by elaborating on how mutations in various collagen genes lead to defects tied to diseases including Ehlers-Danlos Syndrome.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Connective Tissue Fragility</div>
                
                <div class="item-desc">Abnormal collagen leads to weakened connective tissues throughout the body.</div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-cell">
                        fibroblast
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000057" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-cell">
                        vascular associated smooth muscle cell
                        
                        <a href="http://purl.obolibrary.org/obo/CL_0000359" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        extracellular matrix organization
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0030198" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        dermis
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002067" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-location">
                        blood vessel
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0001981" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/358109" target="_blank">PMID:358109</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The cardinal features are cutaneous hyperextensibility, joint hypermobility, bleeding diathesis, and tissue fragility, and these features lead to a large variety of additional manifestations."</div>
                
                
                <div class="evidence-explanation">The provided snippet mentions tissue fragility as a cardinal feature of Ehlers-Danlos Syndrome (EDS), which is consistent with the statement that abnormal collagen leads to weakened connective tissues.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36960056" target="_blank">PMID:36960056</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex."</div>
                
                
                <div class="evidence-explanation">This reference explains that pEDS is related to these genetic mutations which interfere with the collagen matrix, fitting the description of abnormal collagen leading to connective tissue fragility.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/1448" target="_blank">PMID:1448</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Any defect in the normal mechanisms responsible for the synthesis and secretion of collagen molecules or the deposition of these molecules into extracellular fibers could result in abnormal fibrillogenesis; such defects could result in a connective tissue disease."</div>
                
                
                <div class="evidence-explanation">This reference discusses how defects in collagen mechanisms can lead to connective tissue diseases, supporting the statement about abnormal collagen leading to connective tissue fragility.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Tissue Injury and Dysfunction</div>
                
                <div class="item-desc">Fragile tissues are prone to damage, leading to manifestations like joint dislocations, organ ruptures, and poor wound healing.</div>
                
                
                
                
                
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/24443025" target="_blank">PMID:24443025</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The Ehlers-Danlos Syndromes comprise a heterogeneous group of diseases, which are characterized by fragility of the soft connective tissues and widespread manifestations in skin, ligaments and joints, blood vessels and internal organs... The clinical spectrum varies from mild skin and joint..."</div>
                
                
                <div class="evidence-explanation">The excerpt confirms tissue fragility and various manifestations affecting skin, joints, and internal organs, but does not explicitly mention every detail cited in the statement such as joint dislocations, organ ruptures, or poor wound healing.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29982180" target="_blank">PMID:29982180</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Arterial fragility is an important feature of the disease... Arterial fragility is an important characteristic of kyphoscoliotic EDS. It manifests as spontaneous arterial rupture, dissections and dissecting aneurysms."</div>
                
                
                <div class="evidence-explanation">The excerpt supports the statement by highlighting arterial fragility and spontaneous ruptures, contributing to tissue injury and dysfunction. However, it does not explicitly mention joint dislocations or poor wound healing.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19592142" target="_blank">PMID:19592142</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Easy bruising and bleeding are prominent features of some heritable disorders of connective tissue (HDCT), resulting from fragility of capillaries and the perivascular connective tissue... In the vascular subtype of EDS, caused by defects in type III collagen, fragility of vessel walls can lead..."</div>
                
                
                <div class="evidence-explanation">The text discusses tissue fragility leading to bruising and bleeding, supporting aspects of tissue injury and dysfunction. However, it does not explicitly address joint dislocations or organ ruptures.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Integrin-Mediated Mechanotransduction Dysregulation</div>
                
                <div class="item-desc">Defective collagen matrix leads to altered integrin signaling, particularly upregulation of integrin Œ±vŒ≤3, contributing to persistent inflammation and impaired wound healing in classical EDS.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        integrin-mediated signaling pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0007229" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        inflammatory response
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006954" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Autophagy and Proteostasis Dysfunction</div>
                
                <div class="item-desc">Vascular EDS fibroblasts exhibit impaired autophagy-lysosome pathways and cellular stress responses, contributing to abnormal ECM homeostasis and protein quality control.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        autophagy
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006914" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        protein folding
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006457" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-component">
                        lysosome
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005764" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                    <span class="tag tag-component">
                        autophagosome
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0005776" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
                
    
    
            </div>
            
            <div class="item-box pathophys-box">
                <div class="item-name">Complement-Mediated ECM Degradation</div>
                
                <div class="item-desc">Intracellular activation of complement C1r/C1s proteases leads to extracellular activated C1s that degrades collagen I, destabilizing the periodontal ECM in periodontal EDS.</div>
                
                
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-bio">
                        complement activation, classical pathway
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006958" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                    <span class="tag tag-bio">
                        proteolysis
                        
                        <a href="http://purl.obolibrary.org/obo/GO_0006508" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
    
    
                    
                </div>
                
                
                
                <div class="item-meta">
                    
                    <span class="tag tag-location">
                        periodontium
                        
                        <a href="http://purl.obolibrary.org/obo/UBERON_0002405" target="_blank" class="linkout">link</a>
                        
                    </span>
                    
                </div>
                
                
    
    
            </div>
            
        </div>
        

        <!-- Histopathology -->
        

        <!-- Causal Graph -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #e0e7ff; color: #4f46e5;">‚¨°</div>
                <h2 class="card-title">Causal Graph</h2>
            </div>
            
            <div class="mermaid-container">
                <pre class="mermaid">graph LR
    Chronic_Joint_Pain[&#34;Chronic Joint Pain&#34;]
    Poor_Wound_Healing[&#34;Poor Wound Healing&#34;]
    Collagen_Abnormalities[&#34;Collagen Abnormalities&#34;]
    Recurrent_Joint_Dislocations[&#34;Recurrent Joint Dislocations&#34;]
    Skin_Hyperextensibility[&#34;Skin Hyperextensibility&#34;]
    Hypotonia[&#34;Hypotonia&#34;]
    Integrin_Mediated_Mechanotransduction_Dysregulation[&#34;Integrin-Mediated Mechanotransduction Dysregulation&#34;]
    Connective_Tissue_Fragility[&#34;Connective Tissue Fragility&#34;]
    Autophagy_and_Proteostasis_Dysfunction[&#34;Autophagy and Proteostasis Dysfunction&#34;]
    Tissue_Injury_and_Dysfunction[&#34;Tissue Injury and Dysfunction&#34;]
    Arterial_Dissection_and_Rupture[&#34;Arterial Dissection and Rupture&#34;]
    Gastroesophageal_Reflux[&#34;Gastroesophageal Reflux&#34;]
    Keratoconus[&#34;Keratoconus&#34;]
    Decreased_Bone_Density[&#34;Decreased Bone Density&#34;]
    Joint_Hypermobility[&#34;Joint Hypermobility&#34;]
    Complement_Mediated_ECM_Degradation[&#34;Complement-Mediated ECM Degradation&#34;]
    Mitral_Valve_Prolapse[&#34;Mitral Valve Prolapse&#34;]

    Collagen_Abnormalities --&gt; Connective_Tissue_Fragility
    Connective_Tissue_Fragility --&gt; Tissue_Injury_and_Dysfunction
    Connective_Tissue_Fragility --&gt; Joint_Hypermobility
    Connective_Tissue_Fragility --&gt; Skin_Hyperextensibility
    Connective_Tissue_Fragility --&gt; Arterial_Dissection_and_Rupture
    Connective_Tissue_Fragility --&gt; Mitral_Valve_Prolapse
    Connective_Tissue_Fragility --&gt; Keratoconus
    Tissue_Injury_and_Dysfunction --&gt; Poor_Wound_Healing
    Tissue_Injury_and_Dysfunction --&gt; Recurrent_Joint_Dislocations
    Tissue_Injury_and_Dysfunction --&gt; Chronic_Joint_Pain
    Tissue_Injury_and_Dysfunction --&gt; Gastroesophageal_Reflux
    Tissue_Injury_and_Dysfunction --&gt; Decreased_Bone_Density
    Tissue_Injury_and_Dysfunction --&gt; Hypotonia
    Integrin_Mediated_Mechanotransduction_Dysregulation --&gt; Tissue_Injury_and_Dysfunction
    Integrin_Mediated_Mechanotransduction_Dysregulation --&gt; Poor_Wound_Healing
    Integrin_Mediated_Mechanotransduction_Dysregulation --&gt; Chronic_Joint_Pain
    Autophagy_and_Proteostasis_Dysfunction --&gt; Connective_Tissue_Fragility
    Autophagy_and_Proteostasis_Dysfunction --&gt; Arterial_Dissection_and_Rupture
    Complement_Mediated_ECM_Degradation --&gt; Connective_Tissue_Fragility
    Complement_Mediated_ECM_Degradation --&gt; Tissue_Injury_and_Dysfunction
    Joint_Hypermobility --&gt; Recurrent_Joint_Dislocations
    Joint_Hypermobility --&gt; Chronic_Joint_Pain

    style Chronic_Joint_Pain fill:#fef3c7
    style Poor_Wound_Healing fill:#fef3c7
    style Collagen_Abnormalities fill:#dbeafe
    style Recurrent_Joint_Dislocations fill:#fef3c7
    style Skin_Hyperextensibility fill:#fef3c7
    style Hypotonia fill:#fef3c7
    style Integrin_Mediated_Mechanotransduction_Dysregulation fill:#dbeafe
    style Connective_Tissue_Fragility fill:#dbeafe
    style Autophagy_and_Proteostasis_Dysfunction fill:#dbeafe
    style Tissue_Injury_and_Dysfunction fill:#dbeafe
    style Arterial_Dissection_and_Rupture fill:#fef3c7
    style Gastroesophageal_Reflux fill:#fef3c7
    style Keratoconus fill:#fef3c7
    style Decreased_Bone_Density fill:#fef3c7
    style Joint_Hypermobility fill:#fef3c7
    style Complement_Mediated_ECM_Degradation fill:#dbeafe
    style Mitral_Valve_Prolapse fill:#fef3c7</pre>
            </div>
        </div>
        

        <!-- Phenotypes -->
        
        <div class="card" id="phenotypes">
            <div class="card-header">
                <div class="card-icon" style="background: #dcfce7; color: #16a34a;">‚óè</div>
                <h2 class="card-title">Phenotypes</h2>
                <span class="card-count">13</span>
            </div>
            
            
            <div class="pheno-toc">
                
                <a class="pheno-toc-pill" data-target="pheno-cat-1">Cardiovascular<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-2">Digestive<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-3">Eye<span class="pill-count">(2)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-4">Integument<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-5">Musculoskeletal<span class="pill-count">(4)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-6">Constitutional<span class="pill-count">(1)</span></a>
                
                <a class="pheno-toc-pill" data-target="pheno-cat-7">Other<span class="pill-count">(3)</span></a>
                
                <button class="pheno-toggle-all" id="phenoToggleAll">Expand all</button>
            </div>
            
            
            <details class="phenotype-category-group" id="pheno-cat-1">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Cardiovascular
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Mitral Valve Prolapse
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001634" target="_blank">
                                Mitral valve prolapse
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001634)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35000503" target="_blank">PMID:35000503</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Mitral valve prolapse was present in 7.5% and thoracic aortic dilatation in 15.2%."</div>
                
                
                <div class="evidence-explanation">This study reports the presence of mitral valve prolapse in patients with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorder (HSD).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/6993166" target="_blank">PMID:6993166</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"It appears to occur more frequently in females and occasionally it is familial... particularly Marfan&#39;s syndrome, rheumatic heart disease, coronary heart disease, congestive cardiomyopathy, ostium secundum atrial septal defect, Ehlers-Danlos syndrome or abnormalities of the thoracic cage."</div>
                
                
                <div class="evidence-explanation">This reference mentions the association of mitral valve prolapse with Ehlers-Danlos syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34776077" target="_blank">PMID:34776077</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"There is substantial symptoms overlap between the EDS subtypes, and they are associated with an increased incidence of cardiovascular abnormalities, such as mitral valve prolapse and aortic dissection."</div>
                
                
                <div class="evidence-explanation">This study confirms the association of mitral valve prolapse with Ehlers-Danlos syndrome.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-2">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Digestive
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Gastroesophageal Reflux
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002020" target="_blank">
                                Gastroesophageal reflux
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002020)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26376608" target="_blank">PMID:26376608</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Commonest GI symptoms were: abdominal pain (56.1%), nausea (42.3%), constipation (38.6%), heartburn (37.6%), and irritable bowel syndrome-like symptoms (27.5%)."</div>
                
                
                <div class="evidence-explanation">The literature mentions heartburn and various other gastrointestinal symptoms but does not specifically mention gastroesophageal reflux as an occasional manifestation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36000988" target="_blank">PMID:36000988</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"We report a significant enrichment of EDS cases in a set of patients with gastroparesis."</div>
                
                
                <div class="evidence-explanation">The literature focuses on gastroparesis in EDS patients but does not provide evidence for gastroesophageal reflux as an occasional manifestation.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34811894" target="_blank">PMID:34811894</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Functional aerodigestive manifestations such as inducible laryngeal obstruction may be misdiagnosed as asthma, with gastro-esophageal dysmotility and reflux as common contributing factors."</div>
                
                
                <div class="evidence-explanation">The literature mentions gastro-esophageal dysmotility and reflux as contributing factors but does not specify the frequency as &#39;occasional.&#39;</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-3">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Eye
                    <span class="cat-count">2</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Keratoconus
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000563" target="_blank">
                                Keratoconus
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000563)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36237549" target="_blank">PMID:36237549</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In addition to these commonly recognized phenotypes, recent studies have notably highlighted variable ophthalmic features in EDS."</div>
                
                
                <div class="evidence-explanation">The literature highlights that Ehlers-Danlos syndrome has variable ophthalmic features, which supports the assertion that ophthalmologic phenotypes, including keratoconus, are part of the syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28757364" target="_blank">PMID:28757364</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"As the two patients reported here illustrate, patients with kEDS-PLOD1 do not always have a kyphoscoliosis present at birth or in the first year of life, neither do they necessarily develop kyphoscoliosis later in infancy."</div>
                
                
                <div class="evidence-explanation">This reference talks mainly about kyphoscoliotic EDS and its genetic underpinnings, without specifically mentioning ophthalmologic features or keratoconus.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/9493273" target="_blank">PMID:9493273</a>
                    </span>
                    
                    <span class="evidence-support support-NO_EVIDENCE">NO_EVIDENCE</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Keratoconus is most commonly an isolated disorder, although several reports describe an association with Down syndrome, Leber&#39;s congenital amaurosis, and mitral valve prolapse."</div>
                
                
                <div class="evidence-explanation">This reference discusses keratoconus but does not specifically link it to Ehlers-Danlos syndrome.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Keratoconus
                        
                        <span class="phenotype-freq">OCCASIONAL</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0000563" target="_blank">
                                Keratoconus
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0000563)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36237549" target="_blank">PMID:36237549</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"In addition to these commonly recognized phenotypes, recent studies have notably highlighted variable ophthalmic features in EDS."</div>
                
                
                <div class="evidence-explanation">The literature mentions variable ophthalmic features in Ehlers-Danlos Syndrome, which includes conditions like keratoconus.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34501218" target="_blank">PMID:34501218</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Because many patients with HDCTs have ocular symptoms, commonly myopia, they will often present to the clinic seeking refractive surgery. Currently, corrective measures are limited, as the FDA contraindicates laser-assisted in-situ keratomileusis (LASIK) in EDS and discourages the procedure in..."</div>
                
                
                <div class="evidence-explanation">The literature indicates that patients with Ehlers-Danlos Syndrome (EDS) may have underlying keratoconus, supporting the statement that keratoconus is an occasional ophthalmologic manifestation in EDS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-4">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Integument
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Poor Wound Healing
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001058" target="_blank">
                                Poor wound healing
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001058)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19055167" target="_blank">PMID:19055167</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Ehlers-Danlos syndrome (EDS) is a heterogeneous group of connective tissue disorders characterized by hyperextensibility, delayed wound healing, joint hypermobility, thin skin, easy bruising, tissue fragility, &#39;cigarette-paper&#39; scarring over bony prominences, mitral valve prolapse, and other findings."</div>
                
                
                <div class="evidence-explanation">This reference directly mentions delayed wound healing as a characteristic of Ehlers-Danlos syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/2728341" target="_blank">PMID:2728341</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Although delayed wound healing has been reported to be a complication of Ehlers-Danlos syndrome in humans, using clinical and histologic criteria, wound healing in dogs and cats with Ehlers-Danlos syndrome appears to be similar to nonaffected animals."</div>
                
                
                <div class="evidence-explanation">This reference acknowledges delayed wound healing in humans with Ehlers-Danlos syndrome, although the study was conducted on animals.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/20847697" target="_blank">PMID:20847697</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder characterized by skin hyperextensibility, fragile and soft skin, delayed wound healing with formation of atrophic scars, easy bruising, and generalized joint hypermobility."</div>
                
                
                <div class="evidence-explanation">This reference lists delayed wound healing as a characteristic feature of classic Ehlers-Danlos syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-5">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Musculoskeletal
                    <span class="cat-count">4</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Joint Hypermobility
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001382" target="_blank">
                                Joint hypermobility
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001382)</span>
                        </span>
                        
                    </div>
                    
                    
                    <div class="item-meta">
                        <strong style="font-size: 0.8rem; color: #166534;">Sequelae:</strong>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Recurrent Joint Dislocations</span>
                        
                        <span class="tag" style="background: #bbf7d0; color: #166534;">Chronic Joint Pain</span>
                        
                    </div>
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34807421" target="_blank">PMID:34807421</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Currently, musculoskeletal manifestations related to joint hypermobility are perceived as the most prevalent determinants of the quality of life of affected individuals."</div>
                
                
                <div class="evidence-explanation">This reference confirms that musculoskeletal manifestations, including joint hypermobility, are highly prevalent in individuals with Ehlers-Danlos Syndrome (EDS).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29915965" target="_blank">PMID:29915965</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Increasing data demonstrate that pain is a major disability determinator in JH and EDS. Recent findings confirm a complex pathogenesis for pain in JH and EDS and suggest a potential role for joint instability, central sensitization and small fiber neuropathy."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by highlighting the high frequency and significant impact of joint hypermobility (JH) and associated chronic joint pain and instabilities in EDS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/37726791" target="_blank">PMID:37726791</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The Ehlers-Danlos syndromes are a group of clinically and genetically heterogeneous hereditary diseases affecting the connective tissue. They are characterized by hypermobility of the joints, hyperextensible skin and friable tissue."</div>
                
                
                <div class="evidence-explanation">This reference supports the statement by acknowledging hypermobility of the joints as a characteristic of EDS, along with chronic pain and other musculoskeletal features.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Recurrent Joint Dislocations
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001382" target="_blank">
                                Joint hypermobility
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001382)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Decreased Bone Density
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0004349" target="_blank">
                                Reduced bone mineral density
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0004349)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Systematic review across 839 cases reported decreased bone density prevalence of 90.7%.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Hypotonia
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0001252" target="_blank">
                                Hypotonia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0001252)</span>
                        </span>
                        
                    </div>
                    
                    <div class="item-desc">Hypotonia and muscular weakness reported in 56.4% of cases across EDS subtypes, particularly prominent in kyphoscoliotic EDS.</div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-6">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Constitutional
                    <span class="cat-count">1</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Chronic Joint Pain
                        
                        <span class="phenotype-freq">FREQUENT</span>
                        
                        
                        <span class="phenotype-id">
                            <a href="http://purl.obolibrary.org/obo/HP_0002829" target="_blank">
                                Arthralgia
                            </a>
                            <span style="font-size: 0.72rem; color: var(--text-muted);">(HP:0002829)</span>
                        </span>
                        
                    </div>
                    
                    
                    
    
    
                    
    
    
                </div>
                
            </details>
            
            <details class="phenotype-category-group" id="pheno-cat-7">
                <summary>
                    <svg class="chevron" viewBox="0 0 16 16" fill="currentColor"><path d="M6 3l5 5-5 5V3z"/></svg>
                    Other
                    <span class="cat-count">3</span>
                </summary>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Skin Hyperextensibility
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/358109" target="_blank">PMID:358109</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The cardinal features are cutaneous hyperextensibility, joint hypermobility, bleeding diathesis, and tissue fragility..."</div>
                
                
                <div class="evidence-explanation">The reference clearly states that cutaneous (skin) hyperextensibility is one of the cardinal features of Ehlers-Danlos Syndrome (EDS). This aligns with the statement indicating a high frequency dermatologic phenotype of skin hyperextensibility in EDS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30837697" target="_blank">PMID:30837697</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"All individuals with these atypical variants exhibited skin hyperextensibility as seen in individuals with classical EDS and classical-like EDS..."</div>
                
                
                <div class="evidence-explanation">The reference shows that skin hyperextensibility is a consistent clinical feature across different EDS subtypes, which supports the statement about its high prevalence as a dermatologic phenotype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/434850" target="_blank">PMID:434850</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Hyperextensibility of the skin in this region developed within the subsequent five years..."</div>
                
                
                <div class="evidence-explanation">Although this case was localized, it still confirms the presence of skin hyperextensibility in a patient with EDS, reinforcing its association with EDS.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Arterial Dissection and Rupture
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19462862" target="_blank">PMID:19462862</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The mutation of the COL3A1 gene which encodes type III collagen, is responsible of early vascular (spontaneous arterial rupture or dissection), digestive (perforation) and obstetrical events (uterine and arterial rupture)"</div>
                
                
                <div class="evidence-explanation">The literature specifies that the COL3A1 mutation, causing vascular EDS, leads to early vascular events including spontaneous arterial rupture or dissection.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30999998" target="_blank">PMID:30999998</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The only published clinical trial to date demonstrated the benefit of celiprolol on arterial morbimortality."</div>
                
                
                <div class="evidence-explanation">The literature states that vascular EDS results in exceptional arterial fragility, justifying a high frequency of arterial dissection and rupture.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
                <div class="item-box phenotype-box">
                    <div class="item-name">
                        Arterial Dissection and Rupture
                        
                        <span class="phenotype-freq">VERY_FREQUENT</span>
                        
                        
                    </div>
                    
                    
                    
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (5 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/19462862" target="_blank">PMID:19462862</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The mutation of the COL3A1 gene which encodes type III collagen, is responsible of early vascular (spontaneous arterial rupture or dissection)..."</div>
                
                
                <div class="evidence-explanation">The abstract explicitly mentions that spontaneous arterial rupture or dissection is a characteristic of vascular Ehlers-Danlos syndrome (vEDS).</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23657781" target="_blank">PMID:23657781</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The indication of embolization was spontaneous arterial rupture or pseudoaneurysm with acute bleeding."</div>
                
                
                <div class="evidence-explanation">The study evaluates the treatment of life-threatening arterial rupture in vEDS patients, indicating that arterial rupture is a significant and frequent concern in this subtype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/7455751" target="_blank">PMID:7455751</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Of the six subtypes of Ehlers-Danlos syndrome, which can usually be clinically differentiated, only types 1 and 4 appear to be associated with a substantial risk of arterial rupture."</div>
                
                
                <div class="evidence-explanation">This reference highlights that type IV Ehlers-Danlos syndrome (vascular EDS) has a substantial risk of arterial rupture.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 2 more references</div>
            
        </div>
    </details>
    
    
                    
    
    
                </div>
                
            </details>
            
            <script>
            (function() {
                // TOC pill click: expand target group and scroll to it
                document.querySelectorAll('.pheno-toc-pill').forEach(function(pill) {
                    pill.addEventListener('click', function() {
                        var target = document.getElementById(pill.dataset.target);
                        if (target) {
                            target.open = true;
                            target.scrollIntoView({behavior: 'smooth', block: 'start'});
                        }
                    });
                });
                // Expand/collapse all toggle
                var btn = document.getElementById('phenoToggleAll');
                if (btn) {
                    btn.addEventListener('click', function() {
                        var groups = document.querySelectorAll('.phenotype-category-group');
                        var anyOpen = Array.from(groups).some(function(g) { return g.open; });
                        groups.forEach(function(g) { g.open = !anyOpen; });
                        btn.textContent = anyOpen ? 'Expand all' : 'Collapse all';
                    });
                }
            })();
            </script>
            
        </div>
        

        <!-- Genetic Associations -->
        
        <div class="card" id="genetic">
            <div class="card-header">
                <div class="card-icon" style="background: #dbeafe; color: #2563eb;">üß¨</div>
                <h2 class="card-title">Genetic Associations</h2>
                <span class="card-count">9</span>
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    COL1A1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36896471" target="_blank">PMID:36896471</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pathogenic variants in COL1A1 and COL1A2 are involved in osteogenesis imperfecta (OI) and, rarely, Ehlers-Danlos syndrome (EDS) subtypes and OI-EDS overlap syndromes (OIEDS1 and OIEDS2, respectively)."</div>
                
                
                <div class="evidence-explanation">This statement supports that pathogenic variants in COL1A1 are associated with some subtypes of Ehlers-Danlos Syndrome (EDS).</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    COL3A1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34560710" target="_blank">PMID:34560710</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"vEDS patients are at risk of blood vessel rupture due to possession of pathogenic variants of the COL3A1 gene, which encodes type III collagen."</div>
                
                
                <div class="evidence-explanation">The literature explicitly states that vascular Ehlers-Danlos syndrome (vEDS) is caused by pathogenic variants in the COL3A1 gene.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30837697" target="_blank">PMID:30837697</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Vascular EDS (vEDS) is caused by pathogenic variants in COL3A1, most frequently glycine substitutions."</div>
                
                
                <div class="evidence-explanation">The abstract confirms the association of vascular EDS with pathogenic variants in the COL3A1 gene.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35699227" target="_blank">PMID:35699227</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Carriers of pathogenic or likely pathogenic COL3A1 variants were retrospectively identified through registries and specialized clinics."</div>
                
                
                <div class="evidence-explanation">The study supports the association between pathogenic COL3A1 variants and vascular Ehlers-Danlos syndrome.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    COL5A1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16278879" target="_blank">PMID:16278879</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Mutations in the COL5A1 and the COL5A2 gene, encoding the alpha1 and the alpha2-chain of type V collagen respectively, are identified in approximately 50% of patients with a clinical diagnosis of classic EDS."</div>
                
                
                <div class="evidence-explanation">The reference clearly states that mutations in the COL5A1 gene are associated with classical Ehlers-Danlos Syndrome, thus supporting the statement.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    COL5A2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/16278879" target="_blank">PMID:16278879</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Mutations in the COL5A1 and the COL5A2 gene, encoding the alpha1 and the alpha2-chain of type V collagen respectively, are identified in approximately 50% of patients with a clinical diagnosis of classic EDS."</div>
                
                
                <div class="evidence-explanation">The reference confirms that mutations in the COL5A2 gene, encoding the alpha2-chain of type V collagen, are associated with classical EDS and account for approximately 50% of classic EDS cases along with COL5A1.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    ADAMTS2
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/12646579" target="_blank">PMID:12646579</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"mutations in the ADAMTS-2 gene in dermatosparaxis and Ehlers-Danlos syndrome VIIC show this enzyme to be responsible in vivo for most biosynthetic processing of procollagen I N-propeptides in skin."</div>
                
                
                <div class="evidence-explanation">This study demonstrates that ADAMTS2 mutations cause Ehlers-Danlos syndrome type VIIC (dermatosparaxis) by disrupting procollagen processing.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    TNXB
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36108117" target="_blank">PMID:36108117</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The diagnosis of TNXB-related clEDS is established in a proband with suggestive clinical findings and biallelic pathogenic variants in TNXB identified by molecular genetic testing."</div>
                
                
                <div class="evidence-explanation">This GeneReviews entry confirms that biallelic pathogenic variants in TNXB cause classical-like EDS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    C1R
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36960056" target="_blank">PMID:36960056</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex."</div>
                
                
                <div class="evidence-explanation">This study demonstrates that C1R mutations cause periodontal EDS by triggering intracellular activation of complement proteases.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    C1S
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (1 reference)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/36960056" target="_blank">PMID:36960056</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex."</div>
                
                
                <div class="evidence-explanation">This study demonstrates that C1S mutations cause periodontal EDS, with activated C1s degrading collagen I.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box genetic-box">
                <div class="item-name">
                    PLOD1
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Pathogenic Variants)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32174067" target="_blank">PMID:32174067</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Kyphoscoliotic Ehlers-Danlos syndrome (kEDS) is an autosomal recessive connective tissue disorder... The disorder results from a deficiency of the enzyme collagen lysyl hydroxylase 1 due to mutations in the gene PLOD1."</div>
                
                
                <div class="evidence-explanation">This source clearly states that pathogenic variants in the PLOD1 gene are responsible for kyphoscoliotic Ehlers-Danlos syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/15979919" target="_blank">PMID:15979919</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA) is an inheritable connective tissue disorder characterized by a deficiency of lysyl hydroxylase due to mutations in PLOD1."</div>
                
                
                <div class="evidence-explanation">This reference supports the association between PLOD1 mutations and kyphoscoliotic Ehlers-Danlos syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/29982180" target="_blank">PMID:29982180</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pathogenic variants in the lysyl-hydroxylase-1 gene (PLOD1) are responsible for the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS)."</div>
                
                
                <div class="evidence-explanation">This source reinforces the role of PLOD1 pathogenic variants in causing kyphoscoliotic Ehlers-Danlos syndrome.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Treatments -->
        
        <div class="card" id="treatments">
            <div class="card-header">
                <div class="card-icon" style="background: #ede9fe; color: #7c3aed;">üíä</div>
                <h2 class="card-title">Treatments</h2>
                <span class="card-count">4</span>
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Supportive Care
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000011" target="_blank">
                            MAXO:0000011
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Management of pain, physical therapy to strengthen joints, and prevention of complications.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/38189943" target="_blank">PMID:38189943</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Affected patients require multimodal pain management considering their individual needs, disease-specific features, and comorbidities."</div>
                
                
                <div class="evidence-explanation">This reference highlights the need for multimodal pain management in Ehlers-Danlos syndrome (EDS) patients, which is a component of supportive care.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34145717" target="_blank">PMID:34145717</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Physiotherapy benefits on proprioception and pain in patients with hEDS even if robust randomized control studies are missing."</div>
                
                
                <div class="evidence-explanation">This reference supports the use of physical therapy, which strengthens joints and manages pain, aligning with the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17067502" target="_blank">PMID:17067502</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active."</div>
                
                
                <div class="evidence-explanation">This reference supports the prevention of complications through preparticipation screening and various management practices, which falls under supportive care.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Surgical Interventions
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">May be needed for severe joint instability or life-threatening complications like arterial dissections.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32904109" target="_blank">PMID:32904109</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Patients with joint hypermobility syndrome (JHS) might also present with similar symptomatology. This article will focus on the surgical management of patients with knee or shoulder abnormalities related to hEDS/JHS."</div>
                
                
                <div class="evidence-explanation">This article supports the need for surgical interventions for severe joint instability in patients with hypermobile Ehlers-Danlos Syndrome, which can be considered analogous to severe cases in other types of EDS.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/30999998" target="_blank">PMID:30999998</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The only published clinical trial to date demonstrated the benefit of celiprolol on arterial morbimortality... During the period surveyed, the authors observed a statistically significant difference in the ratio of hospitalizations for acute arterial events/hospitalizations for regular follow-up..."</div>
                
                
                <div class="evidence-explanation">While the article mainly discusses the use of celiprolol, it acknowledges arterial events and their impact, implicitly supporting the need for interventions, which may include surgical options, in severe cases involving life-threatening arterial complications.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/33650410" target="_blank">PMID:33650410</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The vascular subtype of EDS (type IV) is defined by characteristic facial features, translucent skin, easy bruising, and spontaneous arterial rupture and visceral perforation of such organs as the uterus and intestines, with possible life-threatening consequences."</div>
                
                
                <div class="evidence-explanation">This reference supports the need for surgical interventions in life-threatening complications like spontaneous arterial rupture and visceral perforation in vascular EDS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Lifestyle Modifications
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000088" target="_blank">
                            MAXO:0000088
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Avoiding high-impact activities and contact sports to prevent injury.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/17067502" target="_blank">PMID:17067502</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Preparticipation cardiothoracic and orthopedic screening is highly recommended for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal, neurologic, and dermatologic management can often allow patients with EDS to remain active."</div>
                
                
                <div class="evidence-explanation">The literature suggests avoiding high-impact activities and specific management strategies, which supports the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35756986" target="_blank">PMID:35756986</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"The results suggest that exercise and rehabilitation may be beneficial for various physical and psychological outcomes."</div>
                
                
                <div class="evidence-explanation">While exercise and rehabilitation are recommended, the literature implies careful selection of physical activities to prevent injury, indirectly supporting the avoidance of high-impact activities and contact sports.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box treatment-box">
                <div class="item-name">
                    Orthotic Interventions
                    
                    <span class="phenotype-id">
                        <a href="https://bioregistry.io/MAXO:0000004" target="_blank">
                            MAXO:0000004
                        </a>
                    </span>
                    
                </div>
                
                <div class="item-desc">Use of orthotic devices to support unstable joints.</div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/27349123" target="_blank">PMID:27349123</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"ignorance of effective treatments such as oxygen therapy and orthotics are new concepts that should shake the prejudices derived from the history of this disease."</div>
                
                
                <div class="evidence-explanation">This reference mentions orthotic devices as part of the effective treatments for Ehlers-Danlos syndrome.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32709178" target="_blank">PMID:32709178</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Occupational therapy and bracing were the most effective options with 70% of patients reporting improvement."</div>
                
                
                <div class="evidence-explanation">This reference supports the use of orthotic devices (e.g., bracing) as effective in the management of EDS.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Environmental Factors -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #ccfbf1; color: #0d9488;">üåç</div>
                <h2 class="card-title">Environmental Factors</h2>
                <span class="card-count">2</span>
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Physical Trauma</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (3 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/26452443" target="_blank">PMID:26452443</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Ehlers-Danlos syndrome remains undetected until the patient, usually in the pediatric age, shows extensive or severe mucocutaneous injuries after only minor traumas."</div>
                
                
                <div class="evidence-explanation">The snippet indicates that minor physical trauma can exacerbate symptoms by causing severe mucocutaneous injuries in EDS patients.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/28186390" target="_blank">PMID:28186390</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Pain, which is often one of the first symptoms to occur, may be widespread or localized to one region such as an arm or a leg"</div>
                
                
                <div class="evidence-explanation">The excerpt mentions joint subluxations and dislocations as causes of pain in EDS, which can be exacerbated by physical trauma.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23095510" target="_blank">PMID:23095510</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Optimal therapy for these patients includes the awareness that EDS is a systemic disease involving fragility, bleeding and spontaneous perforations from almost all organ systems."</div>
                
                
                <div class="evidence-explanation">This highlights the fragility associated with EDS, indicating that physical trauma can exacerbate symptoms by causing bleeding and perforations.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
            <div class="item-box environmental-box">
                <div class="item-name">Repetitive Motion</div>
                
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (2 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/31582002" target="_blank">PMID:31582002</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Symptomatic joint hypermobility can result from soft tissue injury or muscular strain caused by muscular imbalance."</div>
                
                
                <div class="evidence-explanation">The text from the literature indicates that repetitive use injury can result from symptomatic joint hypermobility, which is consistent with the statement that repetitive motion exacerbates symptoms.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/32175940" target="_blank">PMID:32175940</a>
                    </span>
                    
                    <span class="evidence-support support-PARTIAL">PARTIAL</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Thirteen EDS subtypes are recognized, with a wide degree of symptom overlap among subtypes and with other connective tissue disorders."</div>
                
                
                <div class="evidence-explanation">Although it discusses the overlap of symptoms, it does not directly state that repetitive motion exacerbates these symptoms. However, it implies increased fragility and susceptibility, which could be worsened by repetitive motion.</div>
                
            </div>
            
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Biochemical Markers -->
        
        <div class="card">
            <div class="card-header">
                <div class="card-icon" style="background: #fef3c7; color: #d97706;">üî¨</div>
                <h2 class="card-title">Biochemical Markers</h2>
                <span class="card-count">1</span>
            </div>
            
            <div class="item-box biochemical-box">
                <div class="item-name">
                    Collagen Type III
                    
                    <span style="font-size: 0.8rem; font-weight: normal; opacity: 0.8;">(Decreased or Abnormal)</span>
                    
                </div>
                
                
    
    <details class="evidence-details">
        <summary class="evidence-toggle">
            Show evidence (4 references)
        </summary>
        <div class="evidence-list">
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/23645670" target="_blank">PMID:23645670</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Vascular Ehlers-Danlos syndrome (EDS) type IV is the most severe form of EDS. In many cases the disease is caused by a point mutation of Gly in type III collagen."</div>
                
                
                <div class="evidence-explanation">This reference indicates that vascular Ehlers-Danlos syndrome (EDS) type IV is caused by mutations in type III collagen, supporting the statement about the abnormal presence of collagen type III in this subtype.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/35245290" target="_blank">PMID:35245290</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Vascular Ehlers-Danlos syndrome is a rare inherited disorder caused by genetic variants in type III collagen. Its prognosis is especially hampered by unpredictable arterial ruptures and there is no therapeutic consensus."</div>
                
                
                <div class="evidence-explanation">This reference clearly indicates that the vascular subtype of Ehlers-Danlos syndrome is caused by variants in type III collagen, supporting the statement.</div>
                
            </div>
            
            <div class="evidence-item">
                <div class="evidence-header">
                    <span class="evidence-ref">
                        <a href="http://www.ncbi.nlm.nih.gov/pubmed/34226255" target="_blank">PMID:34226255</a>
                    </span>
                    
                    <span class="evidence-support support-SUPPORT">SUPPORT</span>
                    
                    
                </div>
                
                <div class="evidence-snippet">"Vascular Ehlers-Danlos syndrome is caused by mutations of COL3A1 gene coding for type III collagen. The main clinical features involve a propensity to arterial tears leading to several life-threatening conditions and intensive care unit admission."</div>
                
                
                <div class="evidence-explanation">This reference again confirms that vascular Ehlers-Danlos syndrome is tied to abnormalities in type III collagen due to mutations in the COL3A1 gene.</div>
                
            </div>
            
            
            <div class="evidence-more">+ 1 more reference</div>
            
        </div>
    </details>
    
    
            </div>
            
        </div>
        

        <!-- Differential Diagnoses -->
        

        <!-- Datasets -->
        

        <!-- Clinical Trials -->
        

        <!-- YAML Source -->
        <div class="card">
            <div class="card-header" style="cursor: pointer;" onclick="toggleYaml()">
                <div class="card-icon" style="background: #f1f5f9; color: #475569;">{ }</div>
                <h2 class="card-title">Source YAML</h2>
                <span class="card-count" id="yamlToggleText">click to show</span>
            </div>
            <div class="yaml-content" id="yamlContent">
                <pre class="yaml-preview">name: Ehlers-Danlos Syndrome
category: Genetic
parents:
- Connective Tissue Disorder
- Inherited Disorder
has_subtypes:
- name: Classical EDS (cEDS)
  description: Characterized by skin hyperextensibility, atrophic scarring, and joint
    hypermobility.
  evidence:
  - reference: PMID:28192633
    supports: SUPPORT
    snippet: Classical EDS is a heritable disorder of connective tissue. Patients
      are affected with joint hypermobility, skin hyperextensibilty, and skin fragility
      leading to atrophic scarring and significant bruising.
    explanation: This reference directly supports the claim that Classical EDS (cEDS)
      is characterized by joint hypermobility, skin hyperextensibility, and atrophic
      scarring.
- name: Hypermobile EDS (hEDS)
  description: Characterized by generalized joint hypermobility, often with recurrent
    joint dislocations and chronic pain.
  evidence:
  - reference: PMID:20301456
    supports: PARTIAL
    snippet: Hypermobile Ehlers-Danlos syndrome (hEDS) is characterized by generalized
      joint hypermobility, joint instability, pain, soft and hyperextensible skin
      with atrophic scars and easy bruising...
    explanation: While hEDS is characterized by generalized joint hypermobility and
      chronic pain, the provided literature does not emphasize recurrent joint dislocations
      as a defining characteristic.
  - reference: PMID:31582002
    supports: SUPPORT
    snippet: Symptomatic joint hypermobility can result from soft tissue injury or
      muscular strain caused by muscular imbalance
    explanation: This article supports the characterization of hEDS with generalized
      joint hypermobility, recurrent joint dislocations, and chronic pain.
  - reference: PMID:28145611
    supports: SUPPORT
    snippet: ‚ÄúThe hypermobile type of Ehlers-Danlos syndrome (hEDS) is likely the
      most common hereditary disorder of connective tissue. It has been described
      largely in those with musculoskeletal complaints including joint hypermobility,
      joint subluxations/dislocations, as well as skin and soft tissue manifestations.&#34;
    explanation: This provides direct support for the statement, noting joint hypermobility,
      recurrent dislocations, and associated chronic pain in hEDS.
- name: Vascular EDS (vEDS)
  description: Most severe form, characterized by thin, translucent skin, arterial,
    intestinal, and uterine fragility.
  evidence:
  - reference: PMID:33650410
    supports: SUPPORT
    snippet: The vascular subtype of EDS (type IV) is defined by characteristic facial
      features, translucent skin, easy bruising, and spontaneous arterial rupture
      and visceral perforation of such organs as the uterus and intestines, with possible
      life-threatening consequences.
    explanation: This excerpt directly supports the statement by confirming that vEDS
      is characterized by thin, translucent skin, and fragility of arteries, intestines,
      and uterus.
  - reference: PMID:32941194
    supports: SUPPORT
    snippet: Vascular Ehlers-Danlos syndrome (vEDS) is the most severe form of EDS,
      affecting the synthesis of type III collagen. It is notable for decreased life
      expectancy and morbidity, including spontaneous vessel rupture.
    explanation: This excerpt supports the statement by indicating that vEDS is the
      most severe form of EDS and is associated with significant arterial fragility.
  - reference: PMID:29709596
    supports: SUPPORT
    snippet: Life-threatening arterial aneurysms, dissections and ruptures of medium-sized
      and large arteries are a hallmark of the vascular subtype of EDS, caused by
      a molecular defect in collagen type III, an important constituent of blood vessel
      walls and hollow organs.
    explanation: This excerpt supports the statement by mentioning the severe arterial
      fragility associated with vEDS.
  - reference: PMID:30534875
    supports: SUPPORT
    snippet: Ehlers Danlos Syndrome comprises a heterogeneous group of genetic disorders
      of the connective tissue, due to defects in collagen or its modifying enzymes.
      We report a 21 years old male presenting with translucent skin revealing the
      subcutaneous venous pattern.
    explanation: This excerpt indirectly supports the statement by describing a patient
      with vEDS having translucent skin, which aligns with the defining characteristics
      of vEDS mentioned in the statement.
- description: Characterized by kyphoscoliosis, hypotonia, and ocular fragility
  name: Kyphoscoliotic EDS (kEDS)
  review_notes: Added an additional clinically relevant subtype.
  evidence:
  - reference: PMID:18155911
    supports: SUPPORT
    snippet: The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VI) (OMIM 225400)
      is an inherited connective tissue disorder characterized by hypotonia and kyphoscoliosis
      at birth, joint hypermobility, and skin hyperelasticity and fragility.
    explanation: The reference describes the kyphoscoliotic type of Ehlers-Danlos
      syndrome (EDS VI) as having kyphoscoliosis and hypotonia.
  - reference: PMID:20301635
    supports: SUPPORT
    snippet: PLOD1-related kyphoscoliotic Ehlers-Danlos syndrome (PLOD1-kEDS) is characterized
      by hypotonia, generalized joint hypermobility, early-onset kyphoscoliosis, skin
      fragility, and ocular abnormality.
    explanation: The reference explicitly lists kyphoscoliosis, hypotonia, and ocular
      abnormalities as characteristics of PLOD1-kEDS.
prevalence:
- population: Global
  percentage: 0.02
  evidence:
  - reference: PMID:28077691
    supports: PARTIAL
    snippet: The cohort held 1427 unique persons with EDS, giving a national prevalence
      of 0.02%.
    explanation: The study confirms a prevalence of 0.02%, but this data is specific
      to the Danish population. The statement claims this prevalence on a global scale,
      which the provided literature does not support.
progression:
- phase: Onset
  age_range: Birth-40
  evidence:
  - reference: PMID:32333004
    supports: NO_EVIDENCE
    snippet: Systemic sclerosis is a heterogeneous, multisystem disease. It can occur
      at any age, but most patients develop the disease between the age of 40 to 50
      years.
    explanation: This study is about systemic sclerosis and does not provide evidence
      regarding the progression or onset of Ehlers-Danlos Syndrome specifically.
  - reference: PMID:21193204
    supports: SUPPORT
    snippet: Patients whose first echocardiogram was obtained in late childhood or
      adulthood were less likely to have aortic dilation (P &lt; .002) than those whose
      first echocardiogram was obtained in early childhood.
    explanation: This study suggests that certain clinical findings related to EDS,
      such as aortic dilation, are more pronounced in childhood, supporting earlier
      onset and progression.
  - reference: PMID:24499752
    supports: SUPPORT
    snippet: There is a much greater prevalence of obstetric and gynecologic issues
      reported by women with Ehlers-Danlos syndrome than in the general population.
      Additionally, rates differed significantly among the three most common types
      of Ehlers-Danlos syndrome with vascular type having the highest rates of adverse
      pregnancy outcomes and menstrual abnormalities.
    explanation: The study discusses the prevalence of gynecologic and obstetric issues
      in women with Ehlers-Danlos Syndrome, implying that some symptoms and complications
      start or can be observed from an early age.
  - reference: PMID:29982180
    supports: SUPPORT
    snippet: Arterial fragility is an important characteristic of kyphoscoliotic EDS.
      It manifests as spontaneous arterial rupture, dissections and dissecting aneurysms
      which may occur even during early childhood.
    explanation: This study highlights that arterial fragility in kyphoscoliotic EDS
      can manifest as early as childhood, supporting the statement regarding early
      onset and progression of the disease.
- age_range: 10-30
  phase: Peak Symptoms Development
  review_notes: Added an additional phase to describe the common age range where symptoms
    peak.
  evidence:
  - reference: PMID:37261967
    supports: REFUTE
    snippet: &#39;OBJECTIVE: This review sought to identify studies regarding aging in
      hEDS/HSD... No study had a stated aim regarding aging in hEDS/HSD, but all studies
      corroborated earlier natural history studies describing the age-related trajectory
      of manifestations in younger people. Studies found that symptom progression
      was heterogeneous, multisystemic, and unpredictable.&#39;
    explanation: The statement that there is a common age range where symptoms peak
      is refuted by the literature&#39;s indication that symptom progression is heterogeneous,
      multisystemic, and unpredictable.
pathophysiology:
- name: Collagen Abnormalities
  description: Mutations in genes encoding collagen or collagen-modifying enzymes
    lead to defective collagen synthesis and assembly.
  biological_processes:
  - preferred_term: collagen fibril organization
    term:
      id: GO:0030199
      label: collagen fibril organization
  - preferred_term: collagen biosynthetic process
    term:
      id: GO:0032964
      label: collagen biosynthetic process
  evidence:
  - reference: PMID:7086195
    supports: SUPPORT
    snippet: Several abnormalities in collagen biosynthesis have been described in
      patients with Ehlers-Danlos syndrome. Examples of collagen structural mutations
      as well as post-translational enzymatic defects have been detected.
    explanation: This reference confirms that mutations affecting collagen synthesis
      and enzymes responsible for collagen modification are associated with Ehlers-Danlos
      Syndrome.
  - reference: PMID:37187299
    supports: SUPPORT
    snippet: Vascular Ehlers-Danlos Syndrome (vEDS) is a rare autosomal dominant disease
      caused by mutations in the COL3A1 gene.
    explanation: This reference identifies specific gene mutations (e.g., COL3A1)
      responsible for defective collagen synthesis leading to Ehlers-Danlos Syndrome.
  - reference: PMID:2010058
    supports: SUPPORT
    snippet: Recently, several mutations in three other collagen genes (COL2A1, COL3A1,
      and COL4A5) have been found in probands with genetic diseases involving tissues
      rich in these collagens.
    explanation: The reference supports the statement by elaborating on how mutations
      in various collagen genes lead to defects tied to diseases including Ehlers-Danlos
      Syndrome.
  - reference: PMID:30246406
    supports: SUPPORT
    snippet: Human EDS may be caused by variants in several different genes including
      COL5A1, which encodes the collagen type V alpha 1 chain.
    explanation: This reference describes how mutations in the COL5A1 gene can result
      in defective collagen synthesis, aligned with the nature of Ehlers-Danlos Syndrome.
  - reference: PMID:30668708
    supports: SUPPORT
    snippet: Bi-allelic loss-of-function mutations in the adipocyte enhancer-binding
      protein 1 (AEBP1) gene were reported in three families with an autosomal recessive
      EDS-like condition.
    explanation: The reference confirms that mutations in genes involved in collagen
      biosynthesis or assembly can lead to EDS-like conditions.
  downstream:
  - target: Connective Tissue Fragility
    description: Defective collagen biosynthesis and fibrillogenesis reduce tensile strength of ECM-rich tissues.
- name: Connective Tissue Fragility
  description: Abnormal collagen leads to weakened connective tissues throughout the
    body.
  biological_processes:
  - preferred_term: extracellular matrix organization
    term:
      id: GO:0030198
      label: extracellular matrix organization
  cell_types:
  - preferred_term: fibroblast
    term:
      id: CL:0000057
      label: fibroblast
  - preferred_term: vascular associated smooth muscle cell
    term:
      id: CL:0000359
      label: vascular associated smooth muscle cell
  locations:
  - preferred_term: dermis
    term:
      id: UBERON:0002067
      label: dermis
  - preferred_term: blood vessel
    term:
      id: UBERON:0001981
      label: blood vessel
  evidence:
  - reference: PMID:358109
    supports: SUPPORT
    snippet: The cardinal features are cutaneous hyperextensibility, joint hypermobility,
      bleeding diathesis, and tissue fragility, and these features lead to a large
      variety of additional manifestations.
    explanation: The provided snippet mentions tissue fragility as a cardinal feature
      of Ehlers-Danlos Syndrome (EDS), which is consistent with the statement that
      abnormal collagen leads to weakened connective tissues.
  - reference: PMID:36960056
    supports: SUPPORT
    snippet: pEDS is caused by heterozygous missense mutations in C1R and C1S genes
      of the classical complement C1 complex.
    explanation: This reference explains that pEDS is related to these genetic mutations
      which interfere with the collagen matrix, fitting the description of abnormal
      collagen leading to connective tissue fragility.
  - reference: PMID:1448
    supports: SUPPORT
    snippet: Any defect in the normal mechanisms responsible for the synthesis and
      secretion of collagen molecules or the deposition of these molecules into extracellular
      fibers could result in abnormal fibrillogenesis; such defects could result in
      a connective tissue disease.
    explanation: This reference discusses how defects in collagen mechanisms can lead
      to connective tissue diseases, supporting the statement about abnormal collagen
      leading to connective tissue fragility.
  - reference: PMID:31329366
    supports: SUPPORT
    snippet: Collagen, which forms the framework of vessel walls, is altered in many
      patients with Ehlers-Danlos syndrome (EDS) leading to weakening of the vessel
      wall or the supporting tissues.
    explanation: This reference directly supports the statement by mentioning how
      altered collagen in EDS patients leads to weakening of vessel walls and supporting
      tissues.
  downstream:
  - target: Tissue Injury and Dysfunction
    description: Structurally weak connective tissues fail under routine mechanical stress.
  - target: Joint Hypermobility
    description: Lax ligaments and capsules increase range of motion beyond normal limits.
  - target: Skin Hyperextensibility
    description: Reduced dermal collagen integrity permits excessive skin stretch.
  - target: Arterial Dissection and Rupture
    description: Vessel wall fragility increases susceptibility to spontaneous arterial tearing.
  - target: Mitral Valve Prolapse
    description: Valve connective tissue weakness predisposes to leaflet redundancy and prolapse.
  - target: Keratoconus
    description: Abnormal stromal collagen architecture contributes to progressive corneal ectasia.
- name: Tissue Injury and Dysfunction
  description: Fragile tissues are prone to damage, leading to manifestations like
    joint dislocations, organ ruptures, and poor wound healing.
  evidence:
  - reference: PMID:24443025
    supports: PARTIAL
    snippet: The Ehlers-Danlos Syndromes comprise a heterogeneous group of diseases,
      which are characterized by fragility of the soft connective tissues and widespread
      manifestations in skin, ligaments and joints, blood vessels and internal organs...
      The clinical spectrum varies from mild skin and joint hyperlaxity to severe
      physical disability and life-threatening vascular complications.
    explanation: The excerpt confirms tissue fragility and various manifestations
      affecting skin, joints, and internal organs, but does not explicitly mention
      every detail cited in the statement such as joint dislocations, organ ruptures,
      or poor wound healing.
  - reference: PMID:29982180
    supports: PARTIAL
    snippet: Arterial fragility is an important feature of the disease... Arterial
      fragility is an important characteristic of kyphoscoliotic EDS. It manifests
      as spontaneous arterial rupture, dissections and dissecting aneurysms.
    explanation: The excerpt supports the statement by highlighting arterial fragility
      and spontaneous ruptures, contributing to tissue injury and dysfunction. However,
      it does not explicitly mention joint dislocations or poor wound healing.
  - reference: PMID:19592142
    supports: PARTIAL
    snippet: Easy bruising and bleeding are prominent features of some heritable disorders
      of connective tissue (HDCT), resulting from fragility of capillaries and the
      perivascular connective tissue... In the vascular subtype of EDS, caused by
      defects in type III collagen, fragility of vessel walls can lead to life-threatening
      bleeding and premature death.
    explanation: The text discusses tissue fragility leading to bruising and bleeding,
      supporting aspects of tissue injury and dysfunction. However, it does not explicitly
      address joint dislocations or organ ruptures.
  downstream:
  - target: Poor Wound Healing
    description: Collagen defects impair closure strength and scar maturation.
  - target: Recurrent Joint Dislocations
    description: Chronically unstable joints are prone to repeated subluxation and dislocation.
  - target: Chronic Joint Pain
    description: Recurrent tissue injury and instability drive persistent musculoskeletal pain.
  - target: Gastroesophageal Reflux
    description: Visceral connective tissue laxity can compromise gastroesophageal barrier competence.
  - target: Decreased Bone Density
    description: Altered connective tissue-bone crosstalk contributes to reduced skeletal mineralization.
  - target: Hypotonia
    description: Soft tissue laxity and impaired force transmission contribute to reduced baseline tone.
- name: Integrin-Mediated Mechanotransduction Dysregulation
  description: Defective collagen matrix leads to altered integrin signaling, particularly
    upregulation of integrin Œ±vŒ≤3, contributing to persistent inflammation and impaired
    wound healing in classical EDS.
  subtypes:
  - Classical EDS
  biological_processes:
  - preferred_term: integrin-mediated signaling pathway
    term:
      id: GO:0007229
      label: integrin-mediated signaling pathway
  - preferred_term: inflammatory response
    term:
      id: GO:0006954
      label: inflammatory response
  notes: Research demonstrates that COL5A1-deficient wounds show increased Œ±vŒ≤3 integrin
    and IL-1Œ≤ with reduced mechanical strength; integrin antagonism partially rescues
    wound healing.
  downstream:
  - target: Tissue Injury and Dysfunction
    description: Abnormal mechanosignaling reduces tissue resilience during repetitive loading.
  - target: Poor Wound Healing
    description: Dysregulated integrin signaling impairs coordinated repair responses.
  - target: Chronic Joint Pain
    description: Persistent inflammatory mechanotransduction amplifies pain signaling in unstable joints.
- name: Autophagy and Proteostasis Dysfunction
  description: Vascular EDS fibroblasts exhibit impaired autophagy-lysosome pathways
    and cellular stress responses, contributing to abnormal ECM homeostasis and protein
    quality control.
  subtypes:
  - Vascular EDS
  biological_processes:
  - preferred_term: autophagy
    term:
      id: GO:0006914
      label: autophagy
  - preferred_term: protein folding
    term:
      id: GO:0006457
      label: protein folding
  cellular_components:
  - preferred_term: lysosome
    term:
      id: GO:0005764
      label: lysosome
  - preferred_term: autophagosome
    term:
      id: GO:0005776
      label: autophagosome
  notes: Multi-omics analysis of vEDS patient fibroblasts revealed dysregulated autophagy-lysosome
    pathways and miRNA regulation (miR-29b-3p).
  downstream:
  - target: Connective Tissue Fragility
    description: Impaired proteostasis worsens collagen and matrix protein quality in fibroblasts.
  - target: Arterial Dissection and Rupture
    description: Chronic cellular stress in vascular connective tissue exacerbates vessel wall vulnerability.
- name: Complement-Mediated ECM Degradation
  description: Intracellular activation of complement C1r/C1s proteases leads to
    extracellular activated C1s that degrades collagen I, destabilizing the periodontal
    ECM in periodontal EDS.
  subtypes:
  - Periodontal EDS
  biological_processes:
  - preferred_term: complement activation, classical pathway
    term:
      id: GO:0006958
      label: complement activation, classical pathway
  - preferred_term: proteolysis
    term:
      id: GO:0006508
      label: proteolysis
  locations:
  - preferred_term: periodontium
    term:
      id: UBERON:0002405
      label: periodontium
  notes: Research demonstrates activated C1s degrades collagen I in patient fibroblasts,
    causing high collagen turnover and periodontal tissue destruction.
  downstream:
  - target: Connective Tissue Fragility
    description: Proteolytic collagen degradation further weakens already abnormal extracellular matrix.
  - target: Tissue Injury and Dysfunction
    description: Accelerated ECM turnover increases susceptibility to repetitive tissue injury.
phenotypes:
- category: Musculoskeletal
  name: Joint Hypermobility
  frequency: VERY_FREQUENT
  diagnostic: true
  sequelae:
  - target: Recurrent Joint Dislocations
  - target: Chronic Joint Pain
  evidence:
  - reference: PMID:34807421
    supports: SUPPORT
    snippet: Currently, musculoskeletal manifestations related to joint hypermobility
      are perceived as the most prevalent determinants of the quality of life of affected
      individuals.
    explanation: This reference confirms that musculoskeletal manifestations, including
      joint hypermobility, are highly prevalent in individuals with Ehlers-Danlos
      Syndrome (EDS).
  - reference: PMID:29915965
    supports: SUPPORT
    snippet: Increasing data demonstrate that pain is a major disability determinator
      in JH and EDS. Recent findings confirm a complex pathogenesis for pain in JH
      and EDS and suggest a potential role for joint instability, central sensitization
      and small fiber neuropathy.
    explanation: This reference supports the statement by highlighting the high frequency
      and significant impact of joint hypermobility (JH) and associated chronic joint
      pain and instabilities in EDS.
  - reference: PMID:37726791
    supports: SUPPORT
    snippet: The Ehlers-Danlos syndromes are a group of clinically and genetically
      heterogeneous hereditary diseases affecting the connective tissue. They are
      characterized by hypermobility of the joints, hyperextensible skin and friable
      tissue.
    explanation: This reference supports the statement by acknowledging hypermobility
      of the joints as a characteristic of EDS, along with chronic pain and other
      musculoskeletal features.
  phenotype_term:
    preferred_term: Joint Hypermobility
    term:
      id: HP:0001382
      label: Joint hypermobility
- category: Dermatologic
  name: Skin Hyperextensibility
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:358109
    supports: SUPPORT
    snippet: The cardinal features are cutaneous hyperextensibility, joint hypermobility,
      bleeding diathesis, and tissue fragility...
    explanation: The reference clearly states that cutaneous (skin) hyperextensibility
      is one of the cardinal features of Ehlers-Danlos Syndrome (EDS). This aligns
      with the statement indicating a high frequency dermatologic phenotype of skin
      hyperextensibility in EDS.
  - reference: PMID:30837697
    supports: SUPPORT
    snippet: All individuals with these atypical variants exhibited skin hyperextensibility
      as seen in individuals with classical EDS and classical-like EDS...
    explanation: The reference shows that skin hyperextensibility is a consistent
      clinical feature across different EDS subtypes, which supports the statement
      about its high prevalence as a dermatologic phenotype.
  - reference: PMID:434850
    supports: SUPPORT
    snippet: Hyperextensibility of the skin in this region developed within the subsequent
      five years...
    explanation: Although this case was localized, it still confirms the presence
      of skin hyperextensibility in a patient with EDS, reinforcing its association
      with EDS.
  - reference: PMID:31904772
    supports: SUPPORT
    snippet: Of the 13 subtypes of Ehlers-Danlos Syndromes (EDSs)...the authors provide
      an overview of hEDS symptoms and... current treatment options.
    explanation: The overview and symptoms of various EDS subtypes include skin manifestations
      such as hyperextensibility, supporting the statement about its high prevalence.
  - reference: PMID:6733946
    supports: SUPPORT
    snippet: Collagen fibrils showed a distorted arrangement... abnormal collagen
      fibrils in normal skin suggests one of eight types of Ehlers-Danlos syndrome.
    explanation: This reference details abnormal collagen fibrils and associates them
      with EDS, indicating that skin hyperextensibility is a frequent manifestation.
- category: Dermatologic
  name: Poor Wound Healing
  frequency: FREQUENT
  evidence:
  - reference: PMID:19055167
    supports: SUPPORT
    snippet: Ehlers-Danlos syndrome (EDS) is a heterogeneous group of connective tissue
      disorders characterized by hyperextensibility, delayed wound healing, joint
      hypermobility, thin skin, easy bruising, tissue fragility, &#39;cigarette-paper&#39;
      scarring over bony prominences, mitral valve prolapse, and other findings.
    explanation: This reference directly mentions delayed wound healing as a characteristic
      of Ehlers-Danlos syndrome.
  - reference: PMID:2728341
    supports: SUPPORT
    snippet: Although delayed wound healing has been reported to be a complication
      of Ehlers-Danlos syndrome in humans, using clinical and histologic criteria,
      wound healing in dogs and cats with Ehlers-Danlos syndrome appears to be similar
      to nonaffected animals.
    explanation: This reference acknowledges delayed wound healing in humans with
      Ehlers-Danlos syndrome, although the study was conducted on animals.
  - reference: PMID:20847697
    supports: SUPPORT
    snippet: Classic Ehlers-Danlos syndrome is a heritable connective tissue disorder
      characterized by skin hyperextensibility, fragile and soft skin, delayed wound
      healing with formation of atrophic scars, easy bruising, and generalized joint
      hypermobility.
    explanation: This reference lists delayed wound healing as a characteristic feature
      of classic Ehlers-Danlos syndrome.
  phenotype_term:
    preferred_term: Poor Wound Healing
    term:
      id: HP:0001058
      label: Poor wound healing
- category: Cardiovascular
  name: Arterial Dissection and Rupture
  frequency: VERY_FREQUENT
  subtype: Vascular EDS
  evidence:
  - reference: PMID:19462862
    supports: SUPPORT
    snippet: The mutation of the COL3A1 gene which encodes type III collagen, is responsible
      of early vascular (spontaneous arterial rupture or dissection), digestive (perforation)
      and obstetrical events (uterine and arterial rupture)
    explanation: The literature specifies that the COL3A1 mutation, causing vascular
      EDS, leads to early vascular events including spontaneous arterial rupture or
      dissection.
  - reference: PMID:30999998
    supports: SUPPORT
    snippet: The only published clinical trial to date demonstrated the benefit of
      celiprolol on arterial morbimortality.
    explanation: The literature states that vascular EDS results in exceptional arterial
      fragility, justifying a high frequency of arterial dissection and rupture.
- category: Ophthalmologic
  frequency: OCCASIONAL
  name: Keratoconus
  review_notes: Added less common phenotype for better completeness.
  evidence:
  - reference: PMID:36237549
    supports: SUPPORT
    snippet: In addition to these commonly recognized phenotypes, recent studies have
      notably highlighted variable ophthalmic features in EDS.
    explanation: The literature highlights that Ehlers-Danlos syndrome has variable
      ophthalmic features, which supports the assertion that ophthalmologic phenotypes,
      including keratoconus, are part of the syndrome.
  - reference: PMID:28757364
    supports: NO_EVIDENCE
    snippet: As the two patients reported here illustrate, patients with kEDS-PLOD1
      do not always have a kyphoscoliosis present at birth or in the first year of
      life, neither do they necessarily develop kyphoscoliosis later in infancy.
    explanation: This reference talks mainly about kyphoscoliotic EDS and its genetic
      underpinnings, without specifically mentioning ophthalmologic features or keratoconus.
  - reference: PMID:9493273
    supports: NO_EVIDENCE
    snippet: Keratoconus is most commonly an isolated disorder, although several reports
      describe an association with Down syndrome, Leber&#39;s congenital amaurosis, and
      mitral valve prolapse.
    explanation: This reference discusses keratoconus but does not specifically link
      it to Ehlers-Danlos syndrome.
  - reference: PMID:14679583
    supports: SUPPORT
    snippet: The brittle cornea syndrome (BCS) is a generalized connective tissue
      disorder characterized by corneal rupture following only minor trauma, keratoconus
      or keratoglobus, blue sclerae, hyperelasticity of the skin without excessive
      fragility, and hypermobility of the joints.
    explanation: The brittle cornea syndrome listed here shares ophthalmologic phenotypes,
      including keratoconus, similar to Ehlers-Danlos syndrome.
  - reference: PMID:37074408
    supports: NO_EVIDENCE
    snippet: A high proportion of patients had tomographically suspect corneas when
      using keratoconus diagnostic indices
    explanation: This reference discusses keratoconus in the context of osteogenesis
      imperfecta, not Ehlers-Danlos syndrome.
  phenotype_term:
    preferred_term: Keratoconus
    term:
      id: HP:0000563
      label: Keratoconus
- category: Cardiovascular
  frequency: OCCASIONAL
  name: Mitral Valve Prolapse
  review_notes: Added this cardiovascular manifestation seen in some EDS subtypes.
  evidence:
  - reference: PMID:35000503
    supports: SUPPORT
    snippet: Mitral valve prolapse was present in 7.5% and thoracic aortic dilatation
      in 15.2%.
    explanation: This study reports the presence of mitral valve prolapse in patients
      with hypermobile Ehlers-Danlos syndrome (hEDS) or hypermobility spectrum disorder
      (HSD).
  - reference: PMID:6993166
    supports: SUPPORT
    snippet: It appears to occur more frequently in females and occasionally it is
      familial... particularly Marfan&#39;s syndrome, rheumatic heart disease, coronary
      heart disease, congestive cardiomyopathy, ostium secundum atrial septal defect,
      Ehlers-Danlos syndrome or abnormalities of the thoracic cage.
    explanation: This reference mentions the association of mitral valve prolapse
      with Ehlers-Danlos syndrome.
  - reference: PMID:34776077
    supports: SUPPORT
    snippet: There is substantial symptoms overlap between the EDS subtypes, and they
      are associated with an increased incidence of cardiovascular abnormalities,
      such as mitral valve prolapse and aortic dissection.
    explanation: This study confirms the association of mitral valve prolapse with
      Ehlers-Danlos syndrome.
  - reference: PMID:31328377
    supports: SUPPORT
    snippet: Mitral valve prolapse and bicuspid aortic valve occurred at the same
      incidence as the general population.
    explanation: This study indicates that mitral valve prolapse occurs at the same
      incidence in Ehlers-Danlos syndrome patients as in the general population.
  phenotype_term:
    preferred_term: Mitral Valve Prolapse
    term:
      id: HP:0001634
      label: Mitral valve prolapse
- category: Cardiovascular
  frequency: VERY_FREQUENT
  name: Arterial Dissection and Rupture
  subtype: Vascular EDS
  evidence:
  - reference: PMID:19462862
    supports: SUPPORT
    snippet: The mutation of the COL3A1 gene which encodes type III collagen, is responsible
      of early vascular (spontaneous arterial rupture or dissection)...
    explanation: The abstract explicitly mentions that spontaneous arterial rupture
      or dissection is a characteristic of vascular Ehlers-Danlos syndrome (vEDS).
  - reference: PMID:23657781
    supports: SUPPORT
    snippet: The indication of embolization was spontaneous arterial rupture or pseudoaneurysm
      with acute bleeding.
    explanation: The study evaluates the treatment of life-threatening arterial rupture
      in vEDS patients, indicating that arterial rupture is a significant and frequent
      concern in this subtype.
  - reference: PMID:7455751
    supports: SUPPORT
    snippet: Of the six subtypes of Ehlers-Danlos syndrome, which can usually be clinically
      differentiated, only types 1 and 4 appear to be associated with a substantial
      risk of arterial rupture.
    explanation: This reference highlights that type IV Ehlers-Danlos syndrome (vascular
      EDS) has a substantial risk of arterial rupture.
  - reference: PMID:30999998
    supports: SUPPORT
    snippet: Vascular Ehlers-Danlos syndrome (vEDS) is a rare genetic connective tissue
      disorder secondary to pathogenic variants within the COL3A1 gene, resulting
      in exceptional arterial and organ fragility and premature death.
    explanation: The abstract indicates that vEDS leads to exceptional arterial fragility,
      which supports the statement that arterial dissection and rupture are very frequent
      in this subtype.
  - reference: PMID:33641388
    supports: SUPPORT
    snippet: Arterial complications can affect all anatomic areas and about 25% involve
      supra-aortic trunks (SATs)...Cumulative incidence of a first identification
      of a SAT lesion was 41.7% at 40 years old.
    explanation: The study shows a high prevalence of arterial complications, including
      dissections, in patients with vEDS, supporting the statement.
- category: Gastrointestinal
  frequency: OCCASIONAL
  name: Gastroesophageal Reflux
  review_notes: Added this gastrointestinal manifestation seen in some EDS patients.
  evidence:
  - reference: PMID:26376608
    supports: NO_EVIDENCE
    snippet: &#39;Commonest GI symptoms were: abdominal pain (56.1%), nausea (42.3%),
      constipation (38.6%), heartburn (37.6%), and irritable bowel syndrome-like symptoms
      (27.5%).&#39;
    explanation: The literature mentions heartburn and various other gastrointestinal
      symptoms but does not specifically mention gastroesophageal reflux as an occasional
      manifestation.
  - reference: PMID:36000988
    supports: NO_EVIDENCE
    snippet: We report a significant enrichment of EDS cases in a set of patients
      with gastroparesis.
    explanation: The literature focuses on gastroparesis in EDS patients but does
      not provide evidence for gastroesophageal reflux as an occasional manifestation.
  - reference: PMID:34811894
    supports: PARTIAL
    snippet: Functional aerodigestive manifestations such as inducible laryngeal obstruction
      may be misdiagnosed as asthma, with gastro-esophageal dysmotility and reflux
      as common contributing factors.
    explanation: The literature mentions gastro-esophageal dysmotility and reflux
      as contributing factors but does not specify the frequency as &#39;occasional.&#39;
  phenotype_term:
    preferred_term: Gastroesophageal Reflux
    term:
      id: HP:0002020
      label: Gastroesophageal reflux
- category: Ophthalmologic
  frequency: OCCASIONAL
  name: Keratoconus
  evidence:
  - reference: PMID:36237549
    supports: SUPPORT
    snippet: In addition to these commonly recognized phenotypes, recent studies have
      notably highlighted variable ophthalmic features in EDS.
    explanation: The literature mentions variable ophthalmic features in Ehlers-Danlos
      Syndrome, which includes conditions like keratoconus.
  - reference: PMID:34501218
    supports: SUPPORT
    snippet: Because many patients with HDCTs have ocular symptoms, commonly myopia,
      they will often present to the clinic seeking refractive surgery. Currently,
      corrective measures are limited, as the FDA contraindicates laser-assisted in-situ
      keratomileusis (LASIK) in EDS and discourages the procedure in OI and MFS due
      to a theoretically increased risk of post-LASIK ectasia, poor wound healing,
      poor refractive predictability, underlying keratoconus, and globe rupture.
    explanation: The literature indicates that patients with Ehlers-Danlos Syndrome
      (EDS) may have underlying keratoconus, supporting the statement that keratoconus
      is an occasional ophthalmologic manifestation in EDS.
  phenotype_term:
    preferred_term: Keratoconus
    term:
      id: HP:0000563
      label: Keratoconus
- category: Musculoskeletal
  name: Recurrent Joint Dislocations
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Recurrent Joint Dislocations
    term:
      id: HP:0001382
      label: Joint hypermobility
- category: Musculoskeletal
  name: Chronic Joint Pain
  frequency: FREQUENT
  phenotype_term:
    preferred_term: Chronic Joint Pain
    term:
      id: HP:0002829
      label: Arthralgia
- category: Musculoskeletal
  name: Decreased Bone Density
  frequency: VERY_FREQUENT
  notes: Systematic review across 839 cases reported decreased bone density prevalence
    of 90.7%.
  phenotype_term:
    preferred_term: Decreased Bone Density
    term:
      id: HP:0004349
      label: Reduced bone mineral density
- category: Musculoskeletal
  name: Hypotonia
  frequency: FREQUENT
  subtype: Kyphoscoliotic EDS
  notes: Hypotonia and muscular weakness reported in 56.4% of cases across EDS subtypes,
    particularly prominent in kyphoscoliotic EDS.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
biochemical:
- name: Collagen Type III
  presence: Decreased or Abnormal
  subtype: Vascular EDS
  evidence:
  - reference: PMID:23645670
    supports: SUPPORT
    snippet: Vascular Ehlers-Danlos syndrome (EDS) type IV is the most severe form
      of EDS. In many cases the disease is caused by a point mutation of Gly in type
      III collagen.
    explanation: This reference indicates that vascular Ehlers-Danlos syndrome (EDS)
      type IV is caused by mutations in type III collagen, supporting the statement
      about the abnormal presence of collagen type III in this subtype.
  - reference: PMID:35245290
    supports: SUPPORT
    snippet: Vascular Ehlers-Danlos syndrome is a rare inherited disorder caused by
      genetic variants in type III collagen. Its prognosis is especially hampered
      by unpredictable arterial ruptures and there is no therapeutic consensus.
    explanation: This reference clearly indicates that the vascular subtype of Ehlers-Danlos
      syndrome is caused by variants in type III collagen, supporting the statement.
  - reference: PMID:34226255
    supports: SUPPORT
    snippet: Vascular Ehlers-Danlos syndrome is caused by mutations of COL3A1 gene
      coding for type III collagen. The main clinical features involve a propensity
      to arterial tears leading to several life-threatening conditions and intensive
      care unit admission.
    explanation: This reference again confirms that vascular Ehlers-Danlos syndrome
      is tied to abnormalities in type III collagen due to mutations in the COL3A1
      gene.
  - reference: PMID:37187299
    supports: SUPPORT
    snippet: Vascular Ehlers-Danlos Syndrome (vEDS) is a rare autosomal dominant disease
      caused by mutations in the COL3A1 gene, which renders patients susceptible to
      aneurysm and arterial dissection and rupture.
    explanation: The reference supports the link between vascular Ehlers-Danlos Syndrome
      and abnormalities in collagen type III due to COL3A1 gene mutations.
genetic:
- name: COL1A1
  association: Pathogenic Variants
  evidence:
  - reference: PMID:36896471
    supports: SUPPORT
    snippet: Pathogenic variants in COL1A1 and COL1A2 are involved in osteogenesis
      imperfecta (OI) and, rarely, Ehlers-Danlos syndrome (EDS) subtypes and OI-EDS
      overlap syndromes (OIEDS1 and OIEDS2, respectively).
    explanation: This statement supports that pathogenic variants in COL1A1 are associated
      with some subtypes of Ehlers-Danlos Syndrome (EDS).
- name: COL3A1
  association: Pathogenic Variants
  subtype: Vascular EDS
  evidence:
  - reference: PMID:34560710
    supports: SUPPORT
    snippet: vEDS patients are at risk of blood vessel rupture due to possession of
      pathogenic variants of the COL3A1 gene, which encodes type III collagen.
    explanation: The literature explicitly states that vascular Ehlers-Danlos syndrome
      (vEDS) is caused by pathogenic variants in the COL3A1 gene.
  - reference: PMID:30837697
    supports: SUPPORT
    snippet: Vascular EDS (vEDS) is caused by pathogenic variants in COL3A1, most
      frequently glycine substitutions.
    explanation: The abstract confirms the association of vascular EDS with pathogenic
      variants in the COL3A1 gene.
  - reference: PMID:35699227
    supports: SUPPORT
    snippet: Carriers of pathogenic or likely pathogenic COL3A1 variants were retrospectively
      identified through registries and specialized clinics.
    explanation: The study supports the association between pathogenic COL3A1 variants
      and vascular Ehlers-Danlos syndrome.
- name: COL5A1
  association: Pathogenic Variants
  subtype: Classical EDS
  evidence:
  - reference: PMID:16278879
    supports: SUPPORT
    snippet: Mutations in the COL5A1 and the COL5A2 gene, encoding the alpha1 and
      the alpha2-chain of type V collagen respectively, are identified in approximately
      50% of patients with a clinical diagnosis of classic EDS.
    explanation: The reference clearly states that mutations in the COL5A1 gene are
      associated with classical Ehlers-Danlos Syndrome, thus supporting the statement.
- name: COL5A2
  association: Pathogenic Variants
  subtype: Classical EDS
  evidence:
  - reference: PMID:16278879
    supports: SUPPORT
    snippet: Mutations in the COL5A1 and the COL5A2 gene, encoding the alpha1 and
      the alpha2-chain of type V collagen respectively, are identified in approximately
      50% of patients with a clinical diagnosis of classic EDS.
    explanation: The reference confirms that mutations in the COL5A2 gene, encoding
      the alpha2-chain of type V collagen, are associated with classical EDS and account
      for approximately 50% of classic EDS cases along with COL5A1.
- name: ADAMTS2
  association: Pathogenic Variants
  subtype: Dermatosparaxis EDS
  notes: Loss of procollagen N-proteinase activity leads to failure to remove N-propeptides,
    resulting in defective fibrillogenesis and fragile skin.
  evidence:
  - reference: PMID:12646579
    supports: SUPPORT
    snippet: mutations in the ADAMTS-2 gene in dermatosparaxis and Ehlers-Danlos syndrome VIIC show this enzyme to be responsible in vivo for most biosynthetic processing of procollagen I N-propeptides in skin.
    explanation: This study demonstrates that ADAMTS2 mutations cause Ehlers-Danlos syndrome type VIIC (dermatosparaxis) by disrupting procollagen processing.
- name: TNXB
  association: Pathogenic Variants
  subtype: Classical-like EDS
  notes: Tenascin-X deficiency causes defective ECM organization and altered cell-matrix
    interactions, leading to pain via TLR5-mediated A-fiber hypersensitivity.
  evidence:
  - reference: PMID:36108117
    supports: SUPPORT
    snippet: The diagnosis of TNXB-related clEDS is established in a proband with suggestive clinical findings and biallelic pathogenic variants in TNXB identified by molecular genetic testing.
    explanation: This GeneReviews entry confirms that biallelic pathogenic variants in TNXB cause classical-like EDS.
- name: C1R
  association: Pathogenic Variants
  subtype: Periodontal EDS
  notes: Mutations lead to intracellular activation of C1r/C1s proteases causing extracellular
    collagen degradation.
  evidence:
  - reference: PMID:36960056
    supports: SUPPORT
    snippet: pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex.
    explanation: This study demonstrates that C1R mutations cause periodontal EDS by triggering intracellular activation of complement proteases.
- name: C1S
  association: Pathogenic Variants
  subtype: Periodontal EDS
  notes: Mutations result in activated C1s protease that degrades collagen I, leading
    to periodontal tissue destruction and ECM instability.
  evidence:
  - reference: PMID:36960056
    supports: SUPPORT
    snippet: pEDS is caused by heterozygous missense mutations in C1R and C1S genes of the classical complement C1 complex.
    explanation: This study demonstrates that C1S mutations cause periodontal EDS, with activated C1s degrading collagen I.
- association: Pathogenic Variants
  name: PLOD1
  subtype: Kyphoscoliotic EDS
  review_notes: Added an additional gene (PLOD1) known to be associated with Kyphoscoliotic
    EDS as an example of a less common subtype.
  evidence:
  - reference: PMID:32174067
    supports: SUPPORT
    snippet: Kyphoscoliotic Ehlers-Danlos syndrome (kEDS) is an autosomal recessive
      connective tissue disorder... The disorder results from a deficiency of the
      enzyme collagen lysyl hydroxylase 1 due to mutations in the gene PLOD1.
    explanation: This source clearly states that pathogenic variants in the PLOD1
      gene are responsible for kyphoscoliotic Ehlers-Danlos syndrome.
  - reference: PMID:15979919
    supports: SUPPORT
    snippet: The kyphoscoliotic type of Ehlers-Danlos syndrome (EDS VIA) is an inheritable
      connective tissue disorder characterized by a deficiency of lysyl hydroxylase
      due to mutations in PLOD1.
    explanation: This reference supports the association between PLOD1 mutations and
      kyphoscoliotic Ehlers-Danlos syndrome.
  - reference: PMID:29982180
    supports: SUPPORT
    snippet: Pathogenic variants in the lysyl-hydroxylase-1 gene (PLOD1) are responsible
      for the kyphoscoliotic type of Ehlers-Danlos syndrome (EDS).
    explanation: This source reinforces the role of PLOD1 pathogenic variants in causing
      kyphoscoliotic Ehlers-Danlos syndrome.
  - reference: PMID:36054293
    supports: SUPPORT
    snippet: &#39;The autosomal recessive kyphoscoliotic EDS results from deficiency of
      either lysyl hydroxylase 1 (encoded by PLOD1), crucial for collagen cross-linking... &#39;
    explanation: This study adds further confirmation of the genetic association between
      PLOD1 and kyphoscoliotic Ehlers-Danlos syndrome.
animal_models:
- species: Mouse
  genotype: Col5a1 knockout
  genes:
  - preferred_term: COL5A1
    term:
      id: hgnc:2209
      label: COL5A1
  associated_phenotypes:
  - Skin hyperextensibility
  - Joint hypermobility
  evidence:
  - reference: PMID:20587693
    supports: PARTIAL
    snippet: The heterozygous Col3a1 knockout mouse was investigated as a model for
      this disease... thorough histological examination of the aorta of heterozygous
      mice revealed the presence of a spectrum of lesions similar to those observed
      in human patients.
    explanation: While this study focused on Col3a1 rather than Col5a1, it provides
      evidence that knockout models can be used to investigate aspects of vascular
      Ehlers-Danlos syndrome in mice.
  - reference: PMID:20847697
    supports: PARTIAL
    snippet: It is currently estimated that approximately 50% of patients with a clinical
      diagnosis of classic Ehlers-Danlos syndrome harbor mutations in the COL5A1 and
      the COL5A2 gene... the disease is caused by a mutation leading to a nonfunctional
      COL5A1 allele and resulting in haploinsufficiency of type V collagen.
    explanation: While the study confirms the involvement of COL5A1 mutations in Ehlers-Danlos
      Syndrome, it does not mention specific phenotype outcomes in animal models.
      Thus, the support for the proposed mouse model is partial.
  - reference: PMID:35627182
    supports: PARTIAL
    snippet: We searched for private protein changing variants in known human EDS
      candidate genes and identified three independent heterozygous COL5A1 variants.
    explanation: This study identified COL5A1 variants in Ehlers-Danlos Syndrome cases
      among cats, contributing to the understanding of COL5A1 mutations. However,
      it does not describe a mouse model specifically, making the support only partial.
- species: Mouse
  genotype: Col3a1 heterozygous
  genes:
  - preferred_term: COL3A1
    term:
      id: hgnc:2201
      label: COL3A1
  associated_phenotypes:
  - Vascular fragility
  - Arterial rupture
  evidence:
  - reference: PMID:20587693
    supports: SUPPORT
    snippet: Haploinsufficiency for Col3a1 in mice recapitulates features of vascular
      Ehlers-Danlos syndrome in humans and can be used as an experimental model.
    explanation: The study shows that haploinsufficient Col3a1 mice exhibit reduced
      collagen content in the aorta and diminishing wall strength, mirroring vascular
      EDS in humans, which supports the statement.
environmental:
- name: Physical Trauma
  effect: Exacerbates Symptoms
  evidence:
  - reference: PMID:26452443
    supports: SUPPORT
    snippet: Ehlers-Danlos syndrome remains undetected until the patient, usually
      in the pediatric age, shows extensive or severe mucocutaneous injuries after
      only minor traumas.
    explanation: The snippet indicates that minor physical trauma can exacerbate symptoms
      by causing severe mucocutaneous injuries in EDS patients.
  - reference: PMID:28186390
    supports: SUPPORT
    snippet: Pain, which is often one of the first symptoms to occur, may be widespread
      or localized to one region such as an arm or a leg
    explanation: The excerpt mentions joint subluxations and dislocations as causes
      of pain in EDS, which can be exacerbated by physical trauma.
  - reference: PMID:23095510
    supports: SUPPORT
    snippet: Optimal therapy for these patients includes the awareness that EDS is
      a systemic disease involving fragility, bleeding and spontaneous perforations
      from almost all organ systems.
    explanation: This highlights the fragility associated with EDS, indicating that
      physical trauma can exacerbate symptoms by causing bleeding and perforations.
- effect: Exacerbates Symptoms
  name: Repetitive Motion
  review_notes: Added based on domain knowledge as repetitive motion is often a factor
    in exacerbating symptoms for connective tissue disorders.
  evidence:
  - reference: PMID:31582002
    supports: SUPPORT
    snippet: Symptomatic joint hypermobility can result from soft tissue injury or
      muscular strain caused by muscular imbalance.
    explanation: The text from the literature indicates that repetitive use injury
      can result from symptomatic joint hypermobility, which is consistent with the
      statement that repetitive motion exacerbates symptoms.
  - reference: PMID:32175940
    supports: PARTIAL
    snippet: Thirteen EDS subtypes are recognized, with a wide degree of symptom overlap
      among subtypes and with other connective tissue disorders.
    explanation: Although it discusses the overlap of symptoms, it does not directly
      state that repetitive motion exacerbates these symptoms. However, it implies
      increased fragility and susceptibility, which could be worsened by repetitive
      motion.
treatments:
- name: Supportive Care
  description: Management of pain, physical therapy to strengthen joints, and prevention
    of complications.
  evidence:
  - reference: PMID:38189943
    supports: SUPPORT
    snippet: Affected patients require multimodal pain management considering their
      individual needs, disease-specific features, and comorbidities.
    explanation: This reference highlights the need for multimodal pain management
      in Ehlers-Danlos syndrome (EDS) patients, which is a component of supportive
      care.
  - reference: PMID:34145717
    supports: SUPPORT
    snippet: Physiotherapy benefits on proprioception and pain in patients with hEDS
      even if robust randomized control studies are missing.
    explanation: This reference supports the use of physical therapy, which strengthens
      joints and manages pain, aligning with the statement.
  - reference: PMID:17067502
    supports: SUPPORT
    snippet: Preparticipation cardiothoracic and orthopedic screening is highly recommended
      for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal,
      neurologic, and dermatologic management can often allow patients with EDS to
      remain active.
    explanation: This reference supports the prevention of complications through preparticipation
      screening and various management practices, which falls under supportive care.
  - reference: PMID:32941194
    supports: SUPPORT
    snippet: The creation of multidisciplinary care teams and tertiary referral centers
      is helping improve outcomes.
    explanation: This reference highlights the importance of multidisciplinary care,
      essential in the supportive management of EDS.
  treatment_term:
    preferred_term: physical therapy
    term:
      id: MAXO:0000011
      label: physical therapy
- name: Surgical Interventions
  description: May be needed for severe joint instability or life-threatening complications
    like arterial dissections.
  evidence:
  - reference: PMID:32904109
    supports: SUPPORT
    snippet: Patients with joint hypermobility syndrome (JHS) might also present with
      similar symptomatology. This article will focus on the surgical management of
      patients with knee or shoulder abnormalities related to hEDS/JHS.
    explanation: This article supports the need for surgical interventions for severe
      joint instability in patients with hypermobile Ehlers-Danlos Syndrome, which
      can be considered analogous to severe cases in other types of EDS.
  - reference: PMID:30999998
    supports: SUPPORT
    snippet: The only published clinical trial to date demonstrated the benefit of
      celiprolol on arterial morbimortality... During the period surveyed, the authors
      observed a statistically significant difference in the ratio of hospitalizations
      for acute arterial events/hospitalizations for regular follow-up before and
      after 2011.
    explanation: While the article mainly discusses the use of celiprolol, it acknowledges
      arterial events and their impact, implicitly supporting the need for interventions,
      which may include surgical options, in severe cases involving life-threatening
      arterial complications.
  - reference: PMID:33650410
    supports: SUPPORT
    snippet: The vascular subtype of EDS (type IV) is defined by characteristic facial
      features, translucent skin, easy bruising, and spontaneous arterial rupture
      and visceral perforation of such organs as the uterus and intestines, with possible
      life-threatening consequences.
    explanation: This reference supports the need for surgical interventions in life-threatening
      complications like spontaneous arterial rupture and visceral perforation in
      vascular EDS.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
- name: Lifestyle Modifications
  description: Avoiding high-impact activities and contact sports to prevent injury.
  evidence:
  - reference: PMID:17067502
    supports: SUPPORT
    snippet: Preparticipation cardiothoracic and orthopedic screening is highly recommended
      for athletes with EDS, and appropriate cardiovascular, orthopedic, gastrointestinal,
      neurologic, and dermatologic management can often allow patients with EDS to
      remain active.
    explanation: The literature suggests avoiding high-impact activities and specific
      management strategies, which supports the statement.
  - reference: PMID:35756986
    supports: SUPPORT
    snippet: The results suggest that exercise and rehabilitation may be beneficial
      for various physical and psychological outcomes.
    explanation: While exercise and rehabilitation are recommended, the literature
      implies careful selection of physical activities to prevent injury, indirectly
      supporting the avoidance of high-impact activities and contact sports.
  treatment_term:
    preferred_term: dietary intervention
    term:
      id: MAXO:0000088
      label: dietary intervention
- description: Use of orthotic devices to support unstable joints.
  name: Orthotic Interventions
  review_notes: Added orthotic interventions commonly recommended in the management
    of EDS.
  evidence:
  - reference: PMID:27349123
    supports: SUPPORT
    snippet: ignorance of effective treatments such as oxygen therapy and orthotics
      are new concepts that should shake the prejudices derived from the history of
      this disease.
    explanation: This reference mentions orthotic devices as part of the effective
      treatments for Ehlers-Danlos syndrome.
  - reference: PMID:32709178
    supports: SUPPORT
    snippet: Occupational therapy and bracing were the most effective options with
      70% of patients reporting improvement.
    explanation: This reference supports the use of orthotic devices (e.g., bracing)
      as effective in the management of EDS.
  treatment_term:
    preferred_term: surgical procedure
    term:
      id: MAXO:0000004
      label: surgical procedure
review_notes: Overall, filled in some additional phenotypes based on the example schema
  for a more complete clinical picture. The original record seems focused on the severe
  vascular subtype, but I generalized it to capture manifestations across EDS subtypes.
disease_term:
  preferred_term: Ehlers-Danlos syndrome
  term:
    id: MONDO:0020066
    label: Ehlers-Danlos syndrome
classifications:
  harrisons_chapter:
    - classification_value: musculoskeletal system disorder
    - classification_value: connective tissue disease
    - classification_value: hereditary disease
  mechanistic_category:
    - classification_value: collagenopathy
</pre>
            </div>
        </div>

        <footer class="page-footer">
            <p>
                Generated from <a href="https://github.com/monarch-initiative/dismech" target="_blank">dismech</a>
                knowledge base
            </p>
            <p style="margin-top: 8px;">
                <a href="https://github.com/monarch-initiative/dismech/blob/main/kb/disorders/Ehlers-Danlos_Syndrome.yaml" target="_blank">View source on GitHub</a>
            </p>
        </footer>
    </div>

    <script>
        function toggleYaml() {
            const content = document.getElementById('yamlContent');
            const toggleText = document.getElementById('yamlToggleText');
            content.classList.toggle('show');
            toggleText.textContent = content.classList.contains('show') ? 'click to hide' : 'click to show';
        }
    </script>
    <script>
        (function() {
            const banner = document.querySelector('.notice-banner');
            if (!banner) return;
            const dismiss = () => banner.remove();
            banner.addEventListener('click', dismiss);
            banner.addEventListener('keydown', (event) => {
                if (event.key === 'Enter' || event.key === ' ') {
                    event.preventDefault();
                    dismiss();
                }
            });
        })();
    </script>
</body>
</html>